

2022, Publikationserhebung, Allgemeine Pathologie Heidelberg

Rot: Erst/Letztautorenschaft

*geteilte Erst- oder Letztautorenschaft

PEER-REVIEWED PUBLICATIONS

1. Adeberg S*, Knoll M*, **Koelsche C**, Bernhardt D, Schrimpf D, Sahn F, König L, Harrabi SB, Hörner-Rieber J, Verma V, Bewerunge-Hudler M, Unterberg A, Sturm D, Jungk C, Herold-Mende C, Wick W, von Deimling A, Debus J, Rieken S*, Abdollahi A*. DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma. *Acta Neuropathol.* 2022 Jul;144(1):129-142. (IF 15.88)
2. Akagbosu B*, Tayyebi Z*, Shibu G, Paucar Iza YA, Deep D, Parisotto YF, Fisher L, Pasolli HA, Thevin V, Elmentaite R, Knott M, Hemmers S, Jahn L, Friedrich C, Verter J, Wang ZM, van den Brink M, Gasteiger G, **Grünwald TGP**, Marie JC, Leslie C, Rudensky AY, Brown CC. Novel antigen-presenting cell imparts T_{reg}-dependent tolerance to gut microbiota. *Nature.* 2022 Oct;610(7933):752-760. (IF 69.50)
3. Al-Dabet MM*, Shahzad K*, Elwakiel A*, Sulaj A, Kopf S, Bock F, Gadi I, Zimmermann S, Rana R, Krishnan S, Gupta D, Manoharan J, Fatima S, Nazir S, **Schwab C**, Baber R, Scholz M, Geffers R, Mertens PR, Nawroth PP, Griffin JH, Keller M, Dockendorff C, Kohli S, Isermann B. Reversal of the renal hyperglycemic memory in diabetic kidney disease by targeting sustained tubular p21 expression. *Nat Commun.* 2022 Aug 27;13(1):5062. (IF 17.69)
4. Andrade A, Poth T, **Brobeil A**, Merle U, Chamulitrat W. iPLA2 β -Null Mice Show HCC Protection by an Induction of Cell-Cycle Arrest after Diethylnitrosamine Treatment. *Int J Mol Sci.* 2022 Nov 9;23(22):13760. (IF 6.20)
5. Banys-Paluchowski M, Thill M, Kühn T, Ditsch N, Heil J, Wöckel A, Fallenberg E, Friedrich M, Kümmel S, Müller V, Janni W, Albert US, Bauerfeind I, Blohmer JU, Budach W, Dall P, Fasching P, Fehm T, Gluz O, Harbeck N, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe HH, Krug D, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, **Sinn HP**, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Gerber B. AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022. *Geburtshilfe Frauenheilkd.* 2022 Sep 30;82(10):1031-1043. (IF 2.75)
6. Berthold R, Isfort I, Erkut C, Heinst L, Grünwald I, Wardelmann E, Kindler T, Åman P, **Grünwald TGP**, Cidre-Aranaz F, Trautmann M, Fröhling S, Scholl C, Hartmann W. Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma. *Oncogenesis.* 2022 Apr 22;11(1):20. (IF 6.52)
7. Biermann J, Melms JC, Amin AD, Wang Y, Caprio LA, Karz A, Tagore S, Barrera I, Ibarra-Arellano MA, Andreatta M, Fullerton BT, Gretarsson KH, Sahu V, Mangipudy VS, Nguyen TTT, Nair A, Rogava M, Ho P, Koch PD, Banu M, Humala N, Mahajan A, Walsh ZH, Shah SB, Vaccaro DH, Caldwell B, Mu M, Wünnemann F, Chazotte M, Berhe S, Luoma AM, Driver J, Ingham M, Khan SA, Rapisuwon S, Slingluff CL Jr, Eigentler T, Röcken M, Carvajal R, Atkins MB, Davies MA, Agustinus A, Bakhoun SF, Azizi E, Siegelin M, Lu C, Carmona SJ, Hibshoosh H, Ribas A, Canoll P, Bruce JN, Bi WL, Agrawal P, **Schapiro D**, Hernando E, Macosko EZ, Chen F, Schwartz GK, Izar B. Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. *Cell.* 2022 Jul 7;185(14):2591-2608.e30. (IF 66.85)

8. Billeter AT, Scheurlen KM, Israel B, **Straub BK, Schirmacher P**, Kopf S, Nawroth PP, Müller-Stich BP. Gastric Bypass Resolves Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Low-BMI Patients: A Prospective Cohort Study. *Ann Surg.* 2022 Nov 1;276(5):814-821. (IF 13.78)
9. Bitzer M, Voesch S, Albert J, Bartenstein P, Bechstein W, Blödt S, Brunner T, Dombrowski F, Evert M, Follmann M, La Fougère C, Freudenberger P, Geier A, Gkika E, Götz M, Hammes E, Helmberger T, Hoffmann RT, Hofmann WP, Huppert P, Kautz A, Knötgen G, Körber J, Krug D, Lammert F, Lang H, Langer T, Lenz P, Mahnken A, Meining A, Micke O, Nadalin S, Nguyen HP, Ockenga J, Oldhafer K, Paprottka P, Paradies K, Pereira P, Persigehl T, Plauth M, Plentz R, Pohl J, Riemer J, Reimer P, Ringwald J, Ritterbusch U, Roeb E, Schellhaas B, **Schirmacher P**, Schmid I, Schuler A, von Schweinitz D, Seehofer D, Sinn M, Stein A, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Trojan J, van Thiel I, Tholen R, Vogel A, Vogl T, Vorwerk H, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wittekind C, Wörns MA, Galle P, Malek N. S3-Leitlinie: Diagnostik und Therapie biliärer Karzinome-Kurzversion 2.00-Juni 2021, AWMF-Registernummer 032-053OL. *Z Gastroenterol.* 2022 Feb;60(2):219-238. German. (IF 1.76)
10. Bitzer M, Voesch S, Albert J, Bartenstein P, Bechstein W, Blödt S, Brunner T, Dombrowski F, Evert M, Follmann M, La Fougère C, Freudenberger P, Geier A, Gkika E, Götz M, Hammes E, Helmberger T, Hoffmann RT, Hofmann WP, Huppert P, Kautz A, Knötgen G, Körber J, Krug D, Lammert F, Lang H, Langer T, Lenz P, Mahnken A, Meining A, Micke O, Nadalin S, Nguyen HP, Ockenga J, Oldhafer K, Paprottka P, Paradies K, Pereira P, Persigehl T, Plauth M, Plentz R, Pohl J, Riemer J, Reimer P, Ringwald J, Ritterbusch U, Roeb E, Schellhaas B, **Schirmacher P**, Schmid I, Schuler A, von Schweinitz D, Seehofer D, Sinn M, Stein A, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Trojan J, van Thiel I, Tholen R, Vogel A, Vogl T, Vorwerk H, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wittekind C, Wörns MA, Galle P, Malek N. S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome-Langversion 2.0-Juni 2021-AWMF-Registernummer 032-053OL. *Z Gastroenterol.* 2022 Feb;60(2):e186-e227. German. (IF 1.76)
11. Blasi M, Eichhorn ME, Christopoulos P, Winter H, Heußel CP, Herth FJ, El Shafie R, Kriegsmann K, **Kriegsmann M, Stenzinger A**, Bischoff H, Thomas M, Kuon J. Major clinical benefit from adjuvant chemotherapy for stage II-III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis. *BMC Pulm Med.* 2022 Jun 28;22(1):255. (IF 3.32)
12. Blickwedel J, Bagci S, Alsat EA, Strizek B, **Renner M**, Müller A, Müller H. DMBT1 amount in amniotic fluid depends on gestational age. *J Matern Fetal Neonatal Med.* 2022 Dec;35(25):7058-7064. (IF 2.32)
13. Bochtler T, Wohlfromm T, Hielscher T, Stichel D, Pouyiourou M, Kraft B, **Neumann O, Endris V**, von Deimling A, **Stenzinger A**, Krämer A. Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary. *Genes Chromosomes Cancer.* 2022 Sep;61(9):551-560. (IF 4.26)
14. Boger M, Bennewitz K, Wohlfart DP, **Hausser I**, Sticht C, Poschet G, Kroll J. Comparative Morphological, Metabolic and Transcriptome Analyses in *elmo1^{-/-}*, *elmo2^{-/-}*, and *elmo3^{-/-}* Zebrafish Mutants Identified a Functional Non-Redundancy of the Elmo Proteins. *Front Cell Dev Biol.* 2022 Jul 8; 10:918529. (IF 6.08)
15. Bohaumilitzky L, Kluck K, Hüneburg R, Gallon R, Nattermann J, **Kirchner M**, Kristiansen G, Hommerding O, Pfuderer PL, Wagner L, Echterdiek F, Kösegi S, Müller N, Fischer K, Nelius N, Hartog B, Borthwick G, Busch E, Haag GM, Bläker H, Möslein G, von Knebel Doeberitz M, Seppälä TT, Ahtianen M, Mecklin JP, Bishop DT, Burn J, **Stenzinger A, Budczies J**, Kloor M*, Ahadova A*. The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients. *Gastroenterology.* 2022 Mar;162(3):907-919.e10. (IF 33.88)

16. Bruch PM*, Giles HA*, Kolb C, Herbst SA, Becirovic T, Roider T, Lu J, Scheinost S, Wagner L, Huellein J, Berest I, **Kriegsmann M**, Kriegsmann K, **Zgorzelski C**, Dreger P, Zaugg JB, Müller-Tidow C, Zenz T, Huber W*, Dietrich S*. Drug-microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL. *Mol Syst Biol*. 2022 Aug;18(8): e10855. (IF 12.74)
17. **Budczies J***, **Kirchner M***, **Kluck K***, **Kazdal D**, **Glade J**, **Allgäuer M**, **Kriegsmann M**, **Heußel CP**, **Herth FJ**, **Winter H**, **Meister M**, **Muley T**, **Goldmann T**, **Fröhling S**, **Wermke M**, **Waller CF**, **Tufman A**, **Reck M**, **Peters S**, **Schirmacher P**, **Thomas M**, **Christopoulos P***, **Stenzinger A***. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. *Cancer Immunol Immunother*. 2022 Feb;71(2):251-265. (IF 6.63)
18. **Budczies J**, **Kluck K**, **Beck S**, **Ourailidis I**, **Allgäuer M**, **Menzel M**, **Kazdal D**, **Perkhofer L**, **Kleger A**, **Schirmacher P**, **Seufferlein T**, **Stenzinger A**. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types. *J Pathol Clin Res*. 2022 Jul;8(4):371-382. (IF 4.37)
19. Cai B, **Bergmann F**, Lu Z, Neoptolemos JP, Li M, Yin L, Gao Y, Xu C, Jiang K, Büchler MW, Miao Y. A histopathological study of artery wall involvement in pancreatic cancer surgery. *Langenbecks Arch Surg*. 2022 Dec;407(8):3501-3511. (IF 2.89)
20. Castven D, Czauderna C, Becker D, Pereira S, **Schmitt J**, Weinmann A, Shah V, Hajduk J, Keggenhoff F, Binder H, Keck T, Heilmann-Heimbach S, Wörns MA, Thorgeirsson SS, **Breuhahn K**, Galle PR, Marquardt JU. Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes-Associated Protein 1 Activation and Transient Expansion of Stem-Like Cancer Cells. *HepatoL Commun*. 2022 May;6(5):1140-1156. (IF 5.70)
21. **Charbel A**, **Tavernar L**, **Albrecht T**, **Brinkmann F**, **Verheij J**, **Roos E**, **Vogel MN**, **Köhler B**, **Springfeld C**, **Brobeil A**, **Schirmacher P**, **Singer S**, **Mehrabi A**, **Roessler S***, **Goeppert B***. Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis. *Br J Cancer*. 2022 Nov;127(9):1603-1614. (IF 9.08)
22. Christgen M, Kandt LD, **Antonopoulos W**, Bartels S, Van Bockstal MR, Bredt M, Brito MJ, Christgen H, Colpaert C, Cserni B, Cserni G, Daemrlich ME, Danebrock R, Dedeurwaerdere F, van Deurzen CH, Erber R, Fathke C, Feist H, Fiche M, Gonzalez CA, Ter Hoeve ND, Kooreman L, Krech T, Kristiansen G, Kulka J, Laenger F, Lafos M, Lehmann U, Martin-Martinez MD, Mueller S, Pelz E, Raap M, Ravarino A, Reineke-Plaass T, Schaumann N, Schelfhout AM, De Schepper M, Schluë J, Van de Vijver K, Waelput W, Wellmann A, Graeser M, Gluz O, Kuemmel S, Nitz U, Harbeck N, Desmedt C, Floris G, Derksen PW, van Diest PJ, Vincent-Salomon A, Kreipe H. Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma. *J Pathol Clin Res*. 2022 Mar;8(2):191-205. (IF 4.37)
23. Christopoulos P, **Kluck K**, **Kirchner M**, Lüders H, Roeper J, Falkenstern-Ge RF, Szewczyk M, Sticht F, Saalfeld FC, Wessler C, Hackanson B, Dintner S, Faehling M, Kuon J, Janning M, Kauffmann-Guerrero D, **Kazdal D**, Kurz S, Eichhorn F, Bozorgmehr F, Shah R, Tufman A, Wermke M, Loges S, Brueckl WM, Schulz C, Misch D, Frost N, Kollmeier J, Reck M, Griesinger F, Grohé C, Hong JL, Lin HM, **Budczies J**, **Stenzinger A**, Thomas M. The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. *Eur J Cancer*. 2022 Jul; 170:106-118. (IF 10.00)
24. **Cidre-Aranaz F**, Li J, **Höling TLB**, **Orth MF**, **Imle R**, **Kutschmann S**, **Ammirati G**, **Ceranski K**, **Carreño-Gonzalez MJ**, **Kasan M**, **Marchetto A**, **Funk CM**, **Bestvater F**, **Bersini S**, **Arrigoni C**, **Moretti M**, **Thiel U**, **Baumhoer D**, **Sahm F**, **Pfister SM**, **Hartmann W**, **Dirksen U**, **Romero-Pérez L**, **Banito A**, **Ohmura S**, **Musa J**, **Kirchner T**, **Knott MML***, **Grünewald TGP***. Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma. *Mol Cancer*. 2022 Jan 3;21(1):1. (IF 41.44)

25. Deininger SO, Bollwein C, Casadonte R, Wandernoth P, Gonçalves JPL, Kriegsmann K, **Kriegsmann M**, Boskamp T, Kriegsmann J, Weichert W, **Schirmacher P**, Ly A, Schwamborn K. Multicenter Evaluation of Tissue Classification by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging. *Anal Chem.* 2022 Jun 14;94(23):8194-8201. (IF 8.00)
26. Delaunay S, Pascual G, Feng B, Klann K, Behm M, Hotz-Wagenblatt A, Richter K, Zaoui K, **Herpel E**, Münch C, Dietmann S, Hess J, Benitah SA, Frye M. Mitochondrial RNA modifications shape metabolic plasticity in metastasis. *Nature.* 2022 Jul;607(7919):593-603. (IF 69.50)
27. Demir S, Wolff G, Wieder A, Maida A, Bühler L, Brune M, Hautzinger O, Feuchtinger A, **Poth T**, Szendroedi J, Herzig S, Ekim Üstünel B. TSC22D4 interacts with Akt1 to regulate glucose metabolism. *Sci Adv.* 2022 Oct 21;8(42): eabo5555. (IF 14.98)
28. Deng Q, Natesan R, Cidre-Aranaz F, Arif S, Liu Y, Rasool RU, Wang P, Mitchell-Velasquez E, Das CK, Vinca E, Cramer Z, Grohar PJ, Chou M, Kumar-Sinha C, Weber K, Eisinger-Mathason TSK, Grillet N, **Grünewald TGP**, Asangani IA. Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1. *Cell Rep.* 2022 Jun 14;39(11):110971. (IF 9.99)
29. Diaz Coronado RY*, Mynarek M*, **Koelsche C**, Mora Alferez P, Casavilca Zambrano S, Wachtel Aptowitz A, Sahn F, von Deimling A, Schüller U, Spohn M, Sturm D, Pfister SM, Morales La Madrid A, Sernaque Quintana R, Sarria Bardales G, Negreiros Chinchihua T, Ojeda Medina L, Garcia-Corrochano Medina P, Campos Sanchez DA, Ponce Farfan J, Rutkowski S*, Garcia Leon JL*. Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients. *Cancer.* 2022 Feb 15;128(4):697-707. (IF 6.92)
30. Diez S, Besendörfer M, Weyerer V, Hartmann A, Moosmann J, Weiss C, **Renner M**, Müller H. DMBT1 expression and neutrophil-to-lymphocyte ratio during necrotizing enterocolitis are influenced by impaired perfusion due to cardiac anomalies. *Mol Cell Pediatr.* 2022 Jan 6;9(1):1. (no IF)
31. Diez S, **Renner M**, Bahlinger V, Hartmann A, Besendörfer M, Müller H. Increased expression of OLFM4 and lysozyme during necrotizing enterocolitis in neonates: an observational research study. *BMC Pediatr.* 2022 Apr 11;22(1):192. (IF 2.56)
32. **Domke LM**, Klein IM, **Hartmann L**, **Schwab C**, Marx A, Werner M, Möller P, Fend F, Bösmüller H, **Schirmacher P**. Biobanking in times of crisis - The COVID-19 Autopsy and Biosample Registry Baden-Wuerttemberg. *Pathol Res Pract.* 2022 Sep; 237:154011. (IF 3.30)
33. Erber R, Angeloni M, Stöhr R, Lux MP, Ulbrich-Gebauer D, Pelz E, Bankfalvi A, Schmid KW, Walter RFH, Vetter M, Thomssen C, Mayr D, Klauschen F, **Sinn P**, Sotlar K, Stering K, **Stenzinger A**, Wunderle M, Fasching PA, Beckmann MW, Hoffmann O, Kimmig R, Harbeck N, Wuerstlein R, Ferrazzi F, Hartmann A. Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting. *Int J Mol Sci.* 2022 Aug 5;23(15):8716. (IF 6.20)
34. Erhart P, Körfer D, Dihlmann S, Qiao JL, **Hausser I**, Ringleb P, Männer J, Dikow N, Schaaf CP, Grond-Ginsbach C, Böckler D. Multiple Arterial Dissections and Connective Tissue Abnormalities. *J Clin Med.* 2022 Jun 7;11(12):3264. (IF 4.96)
35. Felix K, Honda K, Nagashima K, Kashiro A, Takeuchi K, Kobayashi T, Hinterkopf S, **Gaida MM**, Dang H, Brindl N, Kaiser J, Büchler MW, Strobel O. Noninvasive risk stratification of intraductal papillary mucinous neoplasia with malignant potential by serum apolipoprotein-A2-isoforms. *Int J Cancer.* 2022 Mar 1;150(5):881-894. (IF 7.31)
36. Fragoulis A*, Schenkel J*, Schröder N, Brandt EF, Weiand M, Neu T, Ramadori P, Caspers T, Kant S, Pufe T, Mohs A, Trautwein C, **Longerich T**, Streetz KL, Wruck CJ. Nrf2 induces malignant

- transformation of hepatic progenitor cells by inducing β -catenin expression. *Redox Biol.* 2022 Nov;57: 102453. (IF 10.78)
37. Gebhard C, Mulet-Lazaro R, Glatz D, Schwarzfischer-Pfeilschifter L, **Schirmacher P**, Gaedcke J, Weichert W, Reuschel E, Dietmaier W, Rehli M. Aberrant DNA methylation patterns in microsatellite stable human colorectal cancers define a new marker panel for the CpG island methylator phenotype. *Int J Cancer.* 2022 Feb 15;150(4):617-625. (IF 7.31)
 38. Gerber TS, **Goeppert B**, Hausen A, Witzel HR, Bartsch F, Schindeldecker M, Gröger LK, Ridder DA, **Cahyadi O**, Esposito I, Gaida MM, **Schirmacher P**, Galle PR, Lang H, Roth W, Straub BK. N-Cadherin Distinguishes Intrahepatic Cholangiocarcinoma from Liver Metastases of Ductal Adenocarcinoma of the Pancreas. *Cancers (Basel).* 2022 Jun 23;14(13):3091. (IF 6.57)
 39. Gerber TS, Müller L, Bartsch F, Gröger LK, Schindeldecker M, Ridder DA, **Goeppert B**, Möhler M, Dueber C, Lang H, Roth W, Kloeckner R, Straub BK. Integrative Analysis of Intrahepatic Cholangiocarcinoma Subtypes for Improved Patient Stratification: Clinical, Pathological, and Radiological Considerations. *Cancers (Basel).* 2022 Jun 28;14(13):3156. (IF 6.57)
 40. Gerber TS, Ridder DA, Schindeldecker M, Weinmann A, Duret D, **Breuhahn K**, Galle PR, **Schirmacher P**, Roth W, Lang H, Straub BK. Constitutive Occurrence of E:N-cadherin Heterodimers in Adherens Junctions of Hepatocytes and Derived Tumors. *Cells.* 2022 Aug 12;11(16):2507. (IF 7.66)
 41. Ghallab A, Hassan R, Hofmann U, Friebel A, Hobloss Z, Brackhagen L, Begher-Tibbe B, Myllys M, Reinders J, Overbeck N, Sezgin S, Zühlke S, Seddek AL, Murad W, Brecklinghaus T, Kappenberg F, Rahnenführer J, González D, Goldring C, Copple IM, Marchan R, **Longerich T**, Vucur M, Luedde T, Urban S, Canbay A, Schreiter T, Trauner M, Akakpo JY, Olyae M, Curry SC, Sowa JP, Jaeschke H, Hoehme S, Hengstler JG. Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity. *J Hepatol.* 2022 Jul;77(1):71-83. (IF 30.08)
 42. **Goeppert B**, Stichel D, Toth R, **Fritzsche S**, **Loeffler MA**, **Schlitter AM**, **Neumann O**, **Assenov Y**, **Vogel MN**, **Mehrabi A**, **Hoffmann K**, **Köhler B**, **Springfeld C**, **Weichenhan D**, **Plass C**, **Esposito I**, **Schirmacher P**, **von Deimling A**, **Roessler S**. Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis. *Gut.* 2022 Feb;71(2):391-401. (IF 31.79)
 43. Gonçalves JPL, Bollwein C, Schlitter AM, **Kriegsmann M**, Jacob A, Weichert W, Schwamborn K. MALDI-MSI: A Powerful Approach to Understand Primary Pancreatic Ductal Adenocarcinoma and Metastases. *Molecules.* 2022 Jul 27;27(15):4811. (IF 4.92)
 44. Görtz M, Nyarangi-Dix JN, Pursche L, Schütz V, Reimold P, **Schwab C**, **Stenzinger A**, Sültmann H, Duensing S, Schlemmer HP, Bonekamp D, Hohenfellner M, Radtke JP. Impact of Surgeon's Experience in Rigid versus Elastic MRI/TRUS-Fusion Biopsy to Detect Significant Prostate Cancer Using Targeted and Systematic Cores. *Cancers (Basel).* 2022 Feb 10;14(4):886. (IF 6.57)
 45. Grootes I, Keeman R, Blows FM, Milne RL, Giles GG, Swerdlow AJ, Fasching PA, Abubakar M, Andrulis IL, Anton-Culver H, Beckmann MW, Blomqvist C, Bojesen SE, Bolla MK, Bonanni B, Briceno I, Burwinkel B, Camp NJ, Castela JE, Choi JY, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Devilee P, Dörk T, Dunning AM, Dwek M, Easton DF, Eccles DM, Eriksson M, Ernst K, Evans DG, Figueroa JD, Fink V, Floris G, Fox S, Gabrielson M, Gago-Dominguez M, García-Sáenz JA, González-Neira A, Haeberle L, Haiman CA, Hall P, Hamann U, Harkness EF, Hartman M, Hein A, Hooning MJ, Hou MF, Howell SJ; ABCTB Investigators; kConFab Investigators; Ito H, Jakubowska A, Janni W, John EM, Jung A, Kang D, Kristensen VN, Kwong A, Lambrechts D, Li J, Lubiński J, Manoochchri M, Margolin S, Matsuo K, Taib NAM, Mulligan AM, Nevanlinna H, Newman WG, Offit K, Osorio A, Park SK, Park-Simon TW, Patel AV, Presneau N, Pykäs K, Rack B, Radice P, Rennert G, Romero A, Saloustros E, Sawyer EJ, Schneeweiss A, Schochter F, Schoemaker MJ, Shen CY, Shibli R, **Sinn P**, Tapper WJ, Tawfiq E, Teo SH, Teras LR, Torres D, Vachon CM, van Deurzen CHM, Wendt C,

- Williams JA, Winqvist R, Elwood M, Schmidt MK, García-Closas M, Pharoah PDP. Incorporating progesterone receptor expression into the PREDICT breast prognostic model. *Eur J Cancer*. 2022 Sep; 173:178-193. (IF 10.00)
46. Gründing AR, Schneider MA, Richtmann S, **Kriegsmann M**, Winter H, Martinez-Delgado B, Varona S, Liu B, DeLuca DS, Held J, Wrenger S, Muley T, Meister M, Welte T, Janciauskiene S. Lung Adenocarcinoma Cell Sensitivity to Chemotherapies: A Spotlight on Lipid Droplets and *SREBF1* Gene. *Cancers (Basel)*. 2022 Sep 14;14(18):4454. (IF 6.57)
 47. Gupta A*, Singh K*, Fatima S, Ambreen S, Zimmermann S, Younis R, Krishnan S, Rana R, Gadi I, **Schwab C**, Biemann R, Shahzad K, Rani V, Ali S, Mertens PR, Kohli S*, Isermann B. Neutrophil Extracellular Traps Promote NLRP3 Inflammasome Activation and Glomerular Endothelial Dysfunction in Diabetic Kidney Disease. *Nutrients*. 2022 Jul 20;14(14):2965. (IF 6.70)
 48. Hake L, Süßmuth K, Komlosi K, Kopp J, Drerup C, Metze D, Traupe H, **Hausser I**, Eckl KM, Hennies HC, Fischer J, Oji V. Quality of life and clinical characteristics of self-improving congenital ichthyosis within the disease spectrum of autosomal-recessive congenital ichthyosis. *J Eur Acad Dermatol Venereol*. 2022 Apr;36(4):582-591. (IF 9.22)
 49. Hauffe L, Picard D, Musa J, Remke M, **Grünewald TGP**, Rotblat B, Reifenberger G, Leprivier G. Eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1) expression in glioblastoma is driven by ETS1- and MYBL2-dependent transcriptional activation. *Cell Death Discov*. 2022 Feb 28;8(1):91. (IF 7.11)
 50. He L, Boulant S, Stanifer M, Guo C, Nießen A, Chen M, Felix K, **Bergmann F**, Strobel O, Schimmack S. The link between menin and pleiotrophin in the tumor biology of pancreatic neuroendocrine neoplasms. *Cancer Sci*. 2022 May;113(5):1575-1586. (IF 6.51)
 51. Heil J*, Pfob A*, **Sinn HP**, Rauch G, Bach P, Thomas B, Schaeffgen B, Kuemmel S, Reimer T, Hahn M, Thill M, Blohmer JU, Hackmann J, Malter W, Bekes I, Friedrichs K, Wojcinski S, Joos S, Paepke S, Ditsch N, Rody A, Große R, van Mackelenbergh M, Reinisch M, Karsten M, Golatta M; RESPONDER Investigators. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03. *Ann Surg*. 2022 Mar 1;275(3):576-581. (IF 13.78)
 52. Heilig CE*, Laßmann A*, Mughal SS*, Mock A, Pirmann S, Teleanu V, **Renner M**, Andresen C, Köhler BC, Aybey B, Bauer S, Siveke JT, Hamacher R, Folprecht G, Richter S, Schröck E, Brandts CH, Ahrens M, Hohenberger P, Egerer G, Kindler T, Boerries M, Illert AL, von Bubnoff N, Apostolidis L, Jost PJ, Westphalen CB, Weichert W, Keilholz U, Klauschen F, Beck K, Winter U, Richter D, Möhrmann L, Bitzer M, Schulze-Osthoff K, Brors B, **Mechtersheimer G**, Kreutzfeldt S, Heining C, Lipka DB, **Stenzinger A**, Schlenk RF, Horak P, Glimm H*, Hübschmann D*, Fröhling S*. Gene expression-based prediction of pazopanib efficacy in sarcoma. *Eur J Cancer*. 2022 Sep; 172:107-118. (IF 10.00)
 53. Heinze K*, Nazeran TM*, Lee S, Krämer P, Cairns ES, Chiu DS, Leung SC, Kang EY, Meagher NS, Kennedy CJ, Boros J, Kommos F, Vollert HW, Heitz F, du Bois A, Harter P, Grube M, Kraemer B, Staebler A, **Kommos FK**, Heublein S, **Sinn HP**, Singh N, Laslavic A, Elishaev E, Olawaiye A, Moysich K, Modugno F, Sharma R, Brand AH, Harnett PR, DeFazio A, Fortner RT, Lubinski J, Lener M, Tołoczko-Grabarek A, Cybulski C, Gronwald H, Gronwald J, Coulson P, El-Bahrawy MA, Jones ME, Schoemaker MJ, Swerdlow AJ, Goringe KL, Campbell I, Cook L, Gayther SA, Carney ME, Shvetsov YB, Hernandez BY, Wilkens LR, Goodman MT, Mateoiu C, Linder A, Sundfeldt K, Kelemen LE, Gentry-Maharaj A, Widschwendter M, Menon U, Bolton KL, Alsop J, Shah M, Jimenez-Linan M, Pharoah PD, Brenton JD, Cushing-Haugen KL, Harris HR, Doherty JA, Gilks B, Ghatage P, Huntsman DG, Nelson GS, Tinker AV, Lee CH, Goode EL, Nelson BH, Ramus SJ, Kommos S, Talhouk A, Köbel M, Anglesio MS. Validated biomarker assays confirm that ARID1A loss is confounded with MMR

- deficiency, CD8⁺ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. *J Pathol.* 2022 Apr;256(4):388-401. (IF 9.88)
54. Herbst SA*, Vesterlund M*, Helmboldt AJ, Jafari R, Siavelis I, Stahl M, Schitter EC, Liebers N, Brinkmann BJ, Czernilofsky F, Roider T, Bruch PM, Iskar M, Kittai A, Huang Y, Lu J, Richter S, Mermelekas G, Umer HM, Knoll M, Kolb C, Lenze A, Cao X, Österholm C, Wahnschaffe L, Herling C, Scheinost S, Ganzinger M, Mansouri L, Kriegsmann K, **Kriegsmann M**, Anders S, Zapatka M, Del Poeta G, Zucchetto A, Bomben R, Gattei V, Dreger P, Woyach J, Herling M, Müller-Tidow C, Rosenquist R, Stilgenbauer S, Zenz T, Huber W, Tausch E, Lehtiö J, Dietrich S. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia. *Nat Commun.* 2022 Oct 20;13(1):6226. (IF 17.69)
 55. Himbert C, Warby CA, Gigic B, Ose J, Lin T, Viskochil R, Peoples AR, Ashworth A, Schrotz-King P, Scaife CL, Cohan JN, Jedrzakiewicz J, **Schirmacher P**, Grady WM, Cohen SA, Krane M, Figueiredo JC, Toriola AT, Siegel EM, Shibata D, Round JL, Huang LC, Li CI, Schneider M, Ulrich A, Hardikar S, Ulrich CM. Associations of Individual and Combined Physical Activity and Body Mass Index Groups with Proinflammatory Biomarkers among Colorectal Cancer Patients. *Cancer Epidemiol Biomarkers Prev.* 2022 Dec 5;31(12):2148-2156. (IF 4.09)
 56. Hochnadel I*, Hoenicke L*, Petriv N, Neubert L, Reinhard E, Hirsch T, Alfonso JCL, Suo H, **Longerich T**, Geffers R, Lichtinghagen R, Guzmán CA, Wedemeyer H, Lenzen H, Manns MP, Bruder D, Yevsa T. Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated *Listeria monocytogenes* in hepatobiliary cancers. *Oncogene.* 2022 Apr;41(14):2039-2053. doi: 10.1038/s41388-022-02222-z. Epub 2022 Feb 16. Erratum in: *Oncogene.* 2022 Apr 13; PMID: 35173308; PMCID: PMC8853207. (IF 8.75)
 57. Hoffmeister-Wittmann P, Mock A, Nichetti F, Korell F, Heilig CE, Scherr AL, Günther M, **Albrecht T**, Kelmendi E, Xu K, Nader L, Kessler A, Schmitt N, **Fritzsch S**, **Weiler S**, Sobol B, **Stenzinger A**, Boeck S, Westphalen CB, Schulze-Osthoff K, Trojan J, Kindler T, Weichert W, Spiekermann K, Bitzer M, Folprecht G, Illert AL, Boerries M, Klauschen F, Ochsenreither S, Siveke J, Bauer S, Glimm H, Brors B, Hülle J, Hübschmann D, Uhrig S, Horak P, Kreutzfeldt S, Banales JM, Springfield C, Jäger D, **Schirmacher P**, **Roessler S**, Ormanns S, **Goepfert B**, Fröhling S, Köhler BC. Bcl-x_L as prognostic marker and potential therapeutic target in cholangiocarcinoma. *Liver Int.* 2022 Dec;42(12):2855-2870. (IF 8.75)
 58. Holland CH, Ramirez Flores RO, Myllys M, Hassan R, Edlund K, Hofmann U, Marchan R, Cadenas C, Reinders J, Hoehme S, Seddek AL, Dooley S, Keitel V, Godoy P, Begher-Tibbe B, Trautwein C, Rupp C, Mueller S, **Longerich T**, Hengstler JG, Saez-Rodriguez J, Ghallab A. Transcriptomic Cross-Species Analysis of Chronic Liver Disease Reveals Consistent Regulation Between Humans and Mice. *Hepatology Commun.* 2022 Jan;6(1):161-177. (IF 5.70)
 59. **Holl-Ulrich K, Hagel C, Köhler G, Flechtenmacher C. Akkreditierung in der Pathologie und Neuropathologie : Wege und Pitfalls [Accreditation in pathology and neuropathology : Paths and pitfalls]. Pathologie (Heidelb).** 2022 Sep;43(5):338-345. German. (IF 0.97)
 60. Holowatyj AN, Ose J, Gigic B, Lin T, Ulvik A, Geijsen AJMR, Brezina S, Kiblawi R, van Roekel EH, Baierl A, Böhm J, Bours MJL, Brenner H, Breukink SO, Chang-Claude J, de Wilt JHW, Grady WM, Grünberger T, Gumpenberger T, **Herpel E**, Hoffmeister M, Keulen ETP, Kok DE, Koole JL, Kosma K, Kouwenhoven EA, Kvalheim G, Li CI, **Schirmacher P**, Schrotz-King P, Singer MC, van Duijnhoven FJB, van Halteren HK, Vickers K, Vogelaar FJ, Warby CA, Wesselink E, Ueland PM, Ulrich AB, Schneider M, Habermann N, Kampman E, Weijenberg MP, Gsur A, Ulrich CM. Higher vitamin B6 status is associated with improved survival among patients with stage I-III colorectal cancer. *Am J Clin Nutr.* 2022 Aug 4;116(2):303-313. (IF 8.47)
 61. **Hölting TLB, Cidre-Aranaz F, Matzek D, Popper B, Jacobi SJ, Funk CM, Geyer FH, Li J, Piseddu I, Cadilha BL, Ledderose S, Zwilling J, Ohmura S, Anz D, Künkele A, Klauschen F, Grünewald TGP***,

- Knott MML*. Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma. *Mol Cancer*. 2022 Oct 13;21(1):199. (IF 41.44)
62. Hongu T, Pein M, Insua-Rodríguez J, **Gutjahr E**, Mattavelli G, Meier J, Decker K, Descot A, Bozza M, Harbottle R, Trumpp A, **Sinn HP**, Riedel A, Oskarsson T. Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs. *Nat Cancer*. 2022 Apr;3(4):486-504. (IF 23.17)
 63. Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreuzfeldt S, **Stenzinger A**, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). *Genet Med*. 2022 May;24(5):986-998. doi: 10.1016/j.gim.2022.01.001. Epub 2022 Jan 29. Erratum in: *Genet Med*. 2022 Sep;24(9):1991. PMID: 35101336; PMCID: PMC9081216. (IF 8.86)
 64. Hwang WL*, Jagadeesh KA*, Guo JA*, Hoffman HI*, Yadollahpour P, Reeves JW, Mohan R, Drokhyansky E, Van Wittenberghe N, Ashenberg O, Farhi SL, **Schapiro D**, Divakar P, Miller E, Zollinger DR, Eng G, Schenkel JM, Su J, Shiau C, Yu P, Freed-Pastor WA, Abbondanza D, Mehta A, Gould J, Lambden C, Porter CBM, Tsankov A, Dionne D, Waldman J, Cuoco MS, Nguyen L, Delorey T, Phillips D, Barth JL, Kem M, Rodrigues C, Ciprani D, Roldan J, Zelga P, Jorgji V, Chen JH, Ely Z, Zhao D, Fuhrman K, Fropf R, Beechem JM, Loeffler JS, Ryan DP, Weekes CD, Ferrone CR, Qadan M, Aryee MJ, Jain RK, Neuberger DS, Wo JY, Hong TS, Xavier R, Aguirre AJ, Rozenblatt-Rosen O, Mino-Kenudson M, Castillo CF, Liss AS, Ting DT, Jacks T, Regev A. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. *Nat Genet*. 2022 Aug;54(8):1178-1191. (IF 41.376)
 65. Janke F, Angeles AK, Riediger AL, Bauer S, Reck M, **Stenzinger A**, Schneider MA, Muley T, Thomas M, Christopoulos P, Sültmann H. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients. *Clin Epigenetics*. 2022 Dec 2;14(1):163 (IF 7.28)
 66. Janßen C, Boskamp T, Hauberg-Lotte L, Behrmann J, Deininger SO, **Kriegsmann M**, Kriegsmann K, Steinbuß G, Winter H, Muley T, Casadonte R, Kriegsmann J, Maaß P. Robust subtyping of non-small cell lung cancer whole sections through MALDI mass spectrometry imaging. *Proteomics Clin Appl*. 2022 Jul;16(4): e2100068. (IF 3.60)
 67. Janßen C, Boskamp T, Le'Clerc Arrastia J, Otero Baguer D, Hauberg-Lotte L, **Kriegsmann M**, Kriegsmann K, Steinbuß G, Casadonte R, Kriegsmann J, Maaß P. Multimodal Lung Cancer Subtyping Using Deep Learning Neural Networks on Whole Slide Tissue Images and MALDI MSI. *Cancers (Basel)*. 2022 Dec 14;14(24):6181. (IF 6.57)
 68. Jesinghaus M*, Boxberg M*, Schmitt M, **Kriegsmann M**, **Harms A**, Lang C, Muley T, Winter H, Kriegsmann K, Warth A, **Stenzinger A**, Denkert C, Hoffmann H, Safi S, Weichert W. Cellular dissociation grading on biopsies of pulmonary squamous cell carcinoma provides prognostic information across all stages and is congruent with resection specimen grading. *J Pathol Clin Res*. 2022 Nov;8(6):567-578. (IF 4.37)
 69. Ji F, Zhang J, Liu N, Gu Y, Zhang Y, Huang P, Zhang N, Lin S, Pan R, Meng Z, Feng XH, **Roessler S**, Zheng X, Ji J. Blocking hepatocarcinogenesis by a cytochrome P450 family member with female-preferential expression. *Gut*. 2022 Nov;71(11):2313-2324. (IF 31.79)
 70. Kaiser J, Scheifele C, Hinz U, Leonhardt CS, Hank T, Koenig AK, Tjaden C, Hackert T, **Bergmann F**, Büchler MW, Strobel O. IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy. *Eur J Surg Oncol*. 2022 Jun;48(6):1309-1320. (IF 3.18)

71. Kang EY, Millstein J, Popovic G, Meagher NS, Bolithon A, Talhouk A, Chiu DS, Anglesio MS, Leung B, Tang K, Lambie N, Pavanello M, Da-Anoy A, Lambrechts D, Loverix L, Olbrecht S, Bisinotto C, Garcia-Donas J, Ruiz-Llorente S, Yagüe-Fernandez M, Edwards RP, Elishaev E, Olawaiye A, Taylor S, Ataseven B, du Bois A, Harter P, Lester J, Høgdall CK, Armasu SM, Huang Y, Vierkant RA, Wang C, Winham SJ, Heublein S, **Kommoss FKF**, Cramer DW, Sasamoto N, van-Wagensveld L, Lycke M, Mateoiu C, Joseph J, Pike MC, Odunsi K, Tseng CC, Pearce CL, Bilic S, Conrads TP, Hartmann A, Hein A, Jones ME, Leung Y, Beckmann MW, Ruebner M, Schoemaker MJ, Terry KL, El-Bahrawy MA, Coulson P, Etter JL, LaVigne-Mager K, Andress J, Grube M, Fischer A, Neudeck N, Robertson G, Farrell R, Barlow E, Quinn C, Hettiaratchi A, Casablanca Y, Erber R, Stewart CJR, Tan A, Yu Y, Boros J, Brand AH, Harnett PR, Kennedy CJ, Nevins N, Morgan T, Fasching PA, Vergote I, Swerdlow AJ, Candido Dos Reis FJ, Maxwell GL, Neuhausen SL, Barquin-Garcia A, Modugno F, Moysich KB, Crowe PJ, Hirasawa A, Heitz F, Karlan BY, Goode EL, **Sinn P**, Horlings HM, Høgdall E, Sundfeldt K, Kommoss S, Staebler A, Wu AH, Cohen PA, DeFazio A, Lee CH, Steed H, Le ND, Gayther SA, Lawrenson K, Pharoah PDP, Konecny G, Cook LS, Ramus SJ, Kelemen LE, Köbel M. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. *Virchows Arch.* 2022 Apr;480(4):855-871. (IF 4.54)
72. Kantidakis G, Litière S, Gelderblom H, Fiocco M, Judson I, van der Graaf WTA, Italiano A, Marréaud S, Sleijfer S, **Mechtersheimer G**, Messiou C, Kasper B. Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database. *Sarcoma.* 2022 Apr 1; 2022:5815875. (IF 0.71)
73. Kehl N, Kilian M, Michel J, Wagner TR, Uhrig S, **Brobeil A**, Sester LS, Blobner S, Steiger S, Hundemer M, Weinhold N, Rippe K, Fröhling S, Eichmüller SB, Bunse L, Müller-Tidow C, Goldschmidt H, Platten M, Raab MS, Friedrich MJ. IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells. *J Immunother Cancer.* 2022 Oct;10(10):e005815. (IF 12.48)
74. Khomehghir-Silz P, Gerbig S, **Volk N**, Schulz S, Spengler B, Hecker M*, Wagner AH*. Comparative lipid profiling of murine and human atherosclerotic plaques using high-resolution MALDI MSI. *Pflugers Arch.* 2022 Feb;474(2):231-242. (IF 4.45)
75. Kiefer A, Plattner E, Ruppel R, Weiss C, Zhou-Suckow Z, Mall M, **Renner M**, Müller H. DMBT1 is upregulated in cystic fibrosis, affects ciliary motility, and is reduced by acetylcysteine. *Mol Cell Pediatr.* 2022 Mar 5;9(1):4. (no IF)
76. Klimovich B*, Merle N*, Neumann M, Elmshäuser S, Nist A, Mernberger M, **Kazdal D, Stenzinger A**, Timofeev O, Stiewe T. p53 partial loss-of-function mutations sensitize to chemotherapy. *Oncogene.* 2022 Feb;41(7):1011-1023. (IF 8.75)
77. Klotz LV, Hoffmann H, Shah R, Eichhorn F, Gruenewald C, Bulut EL, Griffio R, Muley T, Christopoulos P, Baum P, Huber P, Safi S, **Kriegsmann M**, Thomas M, Bischoff H, Winter H, Eichhorn ME. Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach. *Transl Lung Cancer Res.* 2022 Nov;11(11):2230-2242. (IF 4.72)
78. Koelbel V*, Pfob A*, Schaefgen B, **Sinn P**, Feisst M, Golatta M, Gomez C, Stieber A, Bach P, Rauch G, Heil J. Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment for Reliable Exclusion of Residual Cancer in Breast Cancer Patients. *Ann Surg Oncol.* 2022 Feb;29(2):1076-1084. (IF 4.33)
79. **Kommoss FK, Tessier-Cloutier B, Witkowski L, Forgo E, Koelsche C, Köbel M, Foulkes WD, Lee CH, Kolin DL, von Deimling A*, Howitt BE***. Cellular context determines DNA methylation profiles in SWI/SNF-deficient cancers of the gynecologic tract. *J Pathol.* 2022 Jun;257(2):140-145. (IF 9.88)

80. **Kommos FKF**, Chiang S, Köbel M, **Koelsche C**, Chang KT, Irving JA, Dickson B, Thiryayi S, Rouzbahman M, Rasty G, von Deimling A, Lee CH, Turashvili G. Endometrial Stromal Sarcomas with BCOR Internal Tandem Duplication and Variant BCOR/BCORL1 Rearrangements Resemble High-grade Endometrial Stromal Sarcomas with Recurrent CDK4 Pathway Alterations and MDM2 Amplifications. *Am J Surg Pathol*. 2022 Aug 1;46(8):1142-1152. (IF 6.29)
81. König AK, Gros H, Hinz U, Hank T, Kaiser J, Hackert T, **Bergmann F**, Büchler MW, Strobel O. Refined prognostic staging for resected pancreatic cancer by modified stage grouping and addition of tumour grade. *Eur J Surg Oncol*. 2022 Jan;48(1):113-120. (IF 3.18)
82. Konopa A, Meier MA, Franz MJ, Bernardinelli E, Voegelé AL, Atreya R, Ribback S, **Roessler S**, Aigner A, Singer K, Singer S, Sarikas A, Muehlich S. LPA receptor 1 (LPAR1) is a novel interaction partner of Filamin A that promotes Filamin A phosphorylation, MRTF-A transcriptional activity and oncogene-induced senescence. *Oncogenesis*. 2022 Dec 28;11(1):69. (IF 6.52)
83. Kovalchuk B, Khoramnia R, **Tóth M**, Horner S, Auffarth GU, Augustin VA. Keratitis durch Fusarien – eine zunehmende Bedrohung in Deutschland? [Fusarium Keratitis-an upcoming threat in Germany?]. *Ophthalmologie*. 2022 Oct;119(10):1022-1034. German. (IF 0.99)
84. **Kriegsmann K***, **Lobers F***, **Zgorzelski C**, **Kriegsmann J**, **Janßen C**, **Meliß RR**, **Muley T**, **Sack U**, **Steinbuss G***, **Kriegsmann M***. Deep learning for the detection of anatomical tissue structures and neoplasms of the skin on scanned histopathological tissue sections. *Front Oncol*. 2022 Nov 22;12:1022967. (IF 5.73)
85. Kunz J, Wiedemann C, Grosch H, Kriegsmann K, Gryzik S, Felden J, Hundemer M, **Seher-Cin H**, Stenzinger M, Leo A, **Stenzinger A**, Thomas M, Christopoulos P. Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib. *Cancers (Basel)*. 2022 May 31;14(11):2720. (IF 6.57)
86. Kuppe C*, Ramirez Flores RO*, Li Z*, Hayat S, Levinson RT, Liao X, Hannani MT, Tanevski J, Wünnemann F, Nagai JS, Halder M, Schumacher D, Menzel S, Schäfer G, Hoeft K, Cheng M, Ziegler S, Zhang X, Peisker F, Kaesler N, Saritas T, Xu Y, Kassner A, Gummert J, Morshuis M, Amrute J, Veltrop RJA, Boor P, Klingel K, Van Laake LW, Vink A, Hoogenboezem RM, Bindels EMJ, Schurgers L, Sattler S, **Schapiro D**, Schneider RK, Lavine K, Milting H, Costa IG, Saez-Rodriguez J, Kramann R. Spatial multi-omic map of human myocardial infarction. *Nature*. 2022 Aug;608(7924):766-777. (IF 69.50)
87. Laplana M, Bieg M, Faltus C, Melnik S, Bogatyrova O, Gu Z, Muley T, Meister M, Dienemann H, **Herpel E**, Amos CI, Schlesner M, Eils R, Plass C, Risch A. Differentially methylated regions within lung cancer risk loci are enriched in deregulated enhancers. *Epigenetics*. 2022 Jan-Feb;17(2):117-132. (IF 4.86)
88. **Legnar M**, Daumke P, Hesser J, Porubsky S, Popovic Z, Bindzus JN, Siemoneit JH, **Weis CA**. Natural Language Processing in Diagnostic Texts from Nephropathology. *Diagnostics (Basel)*. 2022 Jul 15;12(7):1726. (IF 3.99)
89. **Leichsenring J***, Vladimirova V*, Solbach C, Karn T, Ataseven B, Sinn BV, Barinoff J, Müller V, Blohmer JU, Schem C, Engels K, Marmé F, Fisseler-Eckhoff A, Fasching PA, Stickeler E, van Mackelenbergh M, Denkert C, **Stenzinger A**, Loibl S, Gröschel S. EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy. *BMC Cancer*. 2022 Oct 5;22(1):1040. (IF 4.63)
90. Liesenfeld LF, Wagner B, Hillebrecht HC, Brune M, **Eckert C**, Klose J, Schmidt T, Büchler MW, Schneider M. HIPEC-Induced Acute Kidney Injury: A Retrospective Clinical Study and Preclinical Model. *Ann Surg Oncol*. 2022 Jan;29(1):139-151. (IF 4.33)
91. Liew DP*, Röhrich M*, Loi L, Adeberg S, Syed M, **Gutjahr E**, Schlemmer HP, Giesel FL, Bendszus M, Haberkorn U, Paech D. FAP-Specific Signalling Is an Independent Diagnostic Approach in ACC

- and Not a Surrogate Marker of MRI Sequences. *Cancers (Basel)*. 2022 Aug 31;14(17):4253. (IF 6.57)
92. Lohse AW, Sebode M, Bhathal PS, Clouston AD, Dienes HP, Jain D, Gouw ASH, Guindi M, Kakar S, Kleiner DE, Krech T, Lackner C, **Longerich T**, Saxena R, Terracciano L, Washington K, Weidemann S, Hübscher SG, Tiniakos D. Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology. *Liver Int*. 2022 May;42(5):1058-1069. (IF 8.75)
 93. Loos M, Mehrabi A, Ramouz A, Contin P, Strobel O, Müller-Stich BP, Mihaljevic AL, Diener MK, Schneider M, Berchtold C, Al-Saeedi M, **Goeppert B**, Mayer P, Feisst M, Hinz U, Weigand MA, Hackert T, Büchler MW. Gastric Venous Congestion After Total Pancreatectomy is Frequent And Dangerous. *Ann Surg*. 2022 Dec 1;276(6): e 896-e904. (IF 13.78)
 94. Luger AL, König S, Samp PF, Urban H, Divé I, Burger MC, Voss M, Franz K, Fokas E, Filipski K, Demes MC, **Stenzinger A**, Sahm F, Reuss DE, Harter PN, Wagner S, Hattingen E, Wichert J, Lapa C, Fröhling S, Steinbach JP, Ronellenfitsch MW. Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis. *J Neurooncol*. 2022 Sep;159(2):243-259. (IF 4.07)
 95. Mohr I, Vogeler M, Pfeiffenberger J, Sprengel SD, Klauss M, Radeleff B, Teufel A, Chang DH, Springfield C, **Longerich T**, Merle U, Mehrabi A, Weiss KH, Mieth M. Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma. *J Cancer Res Clin Oncol*. 2022 Nov;148(11):3163-3174. (IF 4.32)
 96. Möhrmann L*, Werner M*, Oleś M*, Mock A*, Uhrig S*, Jahn A, Kreutzfeldt S, Fröhlich M, Hutter B, Paramasivam N, Richter D, Beck K, Winter U, Pfütze K, Heilig CE, Teleanu V, Lipka DB, Zapatka M, Hanf D, List C, **Allgäuer M**, **Penzel R**, Rüter G, Jelas I, Hamacher R, Falkenhorst J, Wagner S, Brandts CH, Boerries M, Illert AL, Metzeler KH, Westphalen CB, Desuki A, Kindler T, Folprecht G, Weichert W, Brors B, **Stenzinger A**, Schröck E, Hübschmann D, Horak P, Heining C, Fröhling S, Glimm H. Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity. *Nat Commun*. 2022 Aug 2;13(1):4485. (IF 17.69)
 97. Morath C*, Schmitt A*, Schmitt M, Wang L, Kleist C, Opelz G, Süsal C, Tran TH, Scherer S, Schwenger V, Kemmner S, Fischereder M, Stangl M, Hauser IA, Sommerer C, Nussbag C, Kälble F, Speer C, Benning L, Bischofs C, Sauer S, Schubert ML, Kunz A, Hückelhoven-Krauss A, Neuber B, Mehrabi A, **Schwab C**, **Waldherr R**, Sander A, Büsch C, Czock D, Böhmig GA, Reiser J, Roers A, Müller-Tidow C, Terness P, Zeier M, Daniel V*, Schaier M*. Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial. *BMJ Open*. 2022 Nov 11;12(11):e066128. (IF 3.00)
 98. **Neumann O**, **Ball M**, **Lehmann U**, **Schirmacher P**, **Stenzinger A**, **Kazdal D**. Gene und Pathways: FGFR2-Translokationen und Fusionsanalytik [Genes and pathways: FGFR2 translocations and gene fusion analysis]. *Pathologie (Heidelb)*. 2022 Sep;43(5):384-386. German. Erratum in: *Pathologie (Heidelb)*. 2022 Jul 26; PMID: 35925311. (IF 0.97)
 99. **Neumann O**, Burn TC, **Allgäuer M**, **Ball M**, **Kirchner M**, **Albrecht T**, **Volckmar AL**, **Beck S**, **Endris V**, **Goldschmid H**, **Lehmann U**, **Seker-Cin H**, **Uhrig S**, **Roessler S**, **Budczies J**, **Fröhling S**, **Longerich T**, **Wagner AH**, **Vogel A**, **Schirmacher P**, **Stenzinger A**, **Kazdal D**. Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing. *Br J Cancer*. 2022 Nov;127(8):1540-1549. (IF 9.08)

100. Nickel S*, Christ M*, Schmidt S, Kosacka J, Kühne H, Roderfeld M, **Longerich T**, Tietze L, Bosse I, Hsu MJ, Stock P, Roeb E, Christ B. Human Mesenchymal Stromal Cells Resolve Lipid Load in High Fat Diet-Induced Non-Alcoholic Steatohepatitis in Mice by Mitochondria Donation. *Cells*. 2022 Jun 2;11(11):1829. (IF 7.66)
101. Nientiedt C, **Budczies J**, **Endris V**, **Kirchner M**, **Schwab C**, Jurcic C, Behnisch R, Hoveida S, Lantwin P, Kaczorowski A, Geisler C, Dieffenbacher S, Falkenbach F, Franke D, Görtz M, Heller M, Himmelsbach R, Pecqueux C, Rath M, Reimold P, Schütz V, Simunovic I, Walter E, Hofer L, Gasch C, Schönberg G, Pursche L, Hatiboglu G, Nyarangi-Dix J, Sültmann H, Zschäbitz S, Koerber SA, Jäger D, Debus J, Duensing A, **Schirmacher P**, Hohenfellner M, Stenzinger A, Duensing S. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. *Urol Oncol*. 2022 Jan;40(1):8. e11-8. e18. (IF 2.95)
102. **Orth MF**, **Surdez D**, **Faehling T**, **Ehlers AC**, **Marchetto A**, **Grossetête S**, **Volckmann R**, **Zwijenburg DA**, **Gerke JS**, **Zaidi S**, **Alonso J**, **Sastre A**, **Baulande S**, **Sill M**, **Cidre-Aranaz F**, **Ohmura S**, **Kirchner T**, **Hauck SM**, **Reischl E**, **Gymrek M**, **Pfister SM**, **Strauch K**, **Koster J**, **Delattre O**, **Grünewald TGP**. Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation. *Cell Rep*. 2022 Dec 6;41(10):111761. (IF 9.99)
103. Pasello M, Giudice AM, Cristalli C, Manara MC, Mancarella C, Parra A, Serra M, Magagnoli G, Cidre-Aranaz F, **Grünewald TGP**, Bini C, Lollini PL, Longhi A, Donati DM, Scotlandi K. ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis. *Cell Oncol (Dordr)*. 2022 Dec;45(6):1237-1251. **Erratum** in: *Cell Oncol (Dordr)*. 2022 Nov 9; (IF 7.05)
104. Pausch TM, Bartel M, Cui J, Aubert O, Mitzscherling C, Liu X, Gesslein B, Schuisky P, **Kommos FKF**, Bruckner T, Golriz M, Mehrabi A, Hackert T. SmartPAN: In vitro and in vivo proof-of-safety assessments for an intra-operative predictive indicator of postoperative pancreatic fistula. *Basic Clin Pharmacol Toxicol*. 2022 Apr;130(4):542-552. (IF 3.68)
105. **Pellegrino R**, **Castoldi M**, **Ticconi F**, **Skawran B**, **Budczies J**, **Rose F**, **Schwab C**, **Breuhahn K**, **Neumann UP**, **Gaisa NT**, **Loosen SH**, **Luedde T**, **Costa IG**, **Longerich T**. *LINC00152* Drives a Competing Endogenous RNA Network in Human Hepatocellular Carcinoma. *Cells*. 2022 May 3;11(9):1528. (IF 7.66)
106. Peters A; German National Cohort (NAKO) Consortium; Peters A, Greiser KH, Göttlicher S, Ahrens W, Albrecht M, Bamberg F, Bärnighausen T, Becher H, Berger K, Beule A, Boeing H, Bohn B, Bohnert K, Braun B, Brenner H, Bülow R, Castell S, Damms-Machado A, Dörr M, Ebert N, Ecker M, Emmel C, Fischer B, Franzke CW, Gastell S, Giani G, Günther M, Günther K, Günther KP, Haerting J, Haug U, Heid IM, Heier M, Heinemeyer D, Hendel T, Herbolzheimer F, Hirsch J, Hoffmann W, Holleczeck B, Hölling H, Hörlein A, Jöckel KH, Kaaks R, Karch A, Karrasch S, Kartschmit N, Kauczor HU, Keil T, Kemmling Y, Klee B, Klüppelholz B, Kluttig A, Kofink L, Köttgen A, Kraft D, Krause G, Kretz L, Krist L, Kühnisch J, Kuß O, Legath N, Lehnich AT, Leitzmann M, Lieb W, Linseisen J, Loeffler M, Macdonald A, Maier-Hein KH, Mangold N, Meinke-Franze C, Meisinger C, Melzer J, Mergarten B, Michels KB, Mikolajczyk R, Moebus S, Mueller U, Nauck M, Niendorf T, Nikolaou K, Obi N, Ostrzinski S, Panreck L, Pigeot I, Pischon T, Pschibul-Thamm I, Rathmann W, Reineke A, Roloff S, Rujescu D, Rupf S, Sander O, Schikowski T, Schipf S, **Schirmacher P**, Schlett CL, Schmidt B, Schmidt G, Schmidt M, Schöne G, Schulz H, Schulze MB, Schweig A, Sedlmeier AM, Selder S, Six-Merker J, Sowade R, Stang A, Stegle O, Steindorf K, Stübs G, Swart E, Teismann H, Thiele I, Thierry S, Ueffing M, Völzke H, Waniek S, Weber A, Werner N, Wichmann HE, Willich SN, Wirkner K, Wolf K, Wolff R, Zeeb H, Zinkhan M, Zschocke J. Framework and baseline examination of the German National Cohort (NAKO). *Eur J Epidemiol*. 2022 Oct;37(10):1107-1124. (IF 12.44)
107. Pixberg C*, Zapatka M*, Hlevnjak M*, Benedetto S, Suppelna JP, Heil J, Smetanay K, Michel L, Fremd C, Körber V, Rübsam M, Buschhorn L, Heublein S, Schäffgen B, Golatta M, Gomez C, von

- Au A, Wallwiener M, Wolf S, Dikow N, Schaaf C, **Gutjahr E, Allgäuer M, Stenzinger A**, Pfütze K, Kirsten R, Hübschmann D, **Sinn HP**, Jäger D, Trumpp A, Schlenk R, Höfer T, Thewes V, Schneeweiss A*, Lichter P*. COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy. *ESMO Open*. 2022 Dec;7(6):100637. (IF 6.88)
108. **Ploeger C*, Schreck J*, Huth T, Fraas A, Albrecht T, Charbel A**, Ji J, Singer S, **Breuhahn K**, Pusch S, Köhler BC, Springfield C, **Schirmacher P**, Mehrabi A, **Goeppert B, Roessler S**. **STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma. *Cancers (Basel)*. 2022 Feb 23;14(5):1154. (IF 6.57)**
109. Puerto-Camacho P, Díaz-Martín J, Olmedo-Pelayo J, Bolado-Carrancio A, Salguero-Aranda C, Jordán-Pérez C, Esteban-Medina M, Álamo-Álvarez I, Delgado-Bellido D, Lobo-Selma L, Dopazo J, Sastre A, Alonso J, **Grünewald TGP**, Bernabeu C, Byron A, Brunton VG, Amaral AT, de Álava E. Endoglin and MMP14 Contribute to Ewing Sarcoma Spreading by Modulation of Cell-Matrix Interactions. *Int J Mol Sci*. 2022 Aug 4;23(15):8657. (IF 6.20)
110. Qiu R, Alikhanyan K, **Volk N**, Marques O, Mertens C, Agarvas AR, Singh S, Pepperkok R, Altamura S, Muckenthaler MU. Repression of the iron exporter ferroportin may contribute to hepatocyte iron overload in individuals with type 2 diabetes. *Mol Metab*. 2022 Dec; 66:101644. (IF 8.56)
111. Quintavalle C*, Meyer-Schaller N*, **Roessler S**, Calabrese D, Marone R, Riedl T, Picco-Rey S, Panagiotou OA, Uzun S, Piscuoglio S, Boldanova T, Bian CB, Semela D, Jochum W, Cathomas G, Mertz KD, Diebold J, Mazzucchelli L, Koelzer VH, Weber A, Decaens T, Terracciano LM, Heikenwalder M, Hoshida Y, Andersen JB, Thorgeirsson SS, Matter MS. miR-579-3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3-Kinase-Protein Kinase B Pathway in Chronically Inflamed Liver. *Hepatol Commun*. 2022 Jun;6(6):1467-1481. (IF 5.70)
112. Rajakumar T, Horos R, Kittner P, Kahraman M, Sikosek T, Hinkfoth F, Tikk K, Mercaldo ND, **Stenzinger A**, Rabe KF, Reck M, Thomas M, Christopoulos P, Steinkraus BR. Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression. *JTO Clin Res Rep*. 2022 Jun 20;3(8):100369. (no IF)
113. Rajcsanyi LS, Diebels I, Pastoors L, Kanber D, Peters T, **Volckmar AL**, Zheng Y, Grosse M, Dieterich C, Hebebrand J, Kaiser FJ, Horsthemke B, Hinney A. Evidence for correlations between BMI-associated SNPs and circRNAs. *Sci Rep*. 2022 Jul 25;12(1):12643. (IF 4.99)
114. Rasmussen SV, Jin JX, Bickford LR, Woods AD, Sahm F, Crawford KA, Nagamori K, Goto H, Torres KE, Sidoni A, Rudzinski ER, Thway K, Jones RL, Ciulli A, Wright H, Lathara M, Srinivasa G, Kannan K, Huang PH, **Grünewald TGP**, Berlow NE, Keller C. Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology. *Clin Transl Med*. 2022 Jul;12(7):e961. (IF 8.55)
115. Reissig TM, Uhrig S, Jost PJ, Luchini C, Vicentini C, Liffers ST, **Allgäuer M**, Adsay V, Scarpa A, Lawlor RT, Fröhling S, **Stenzinger A**, Klöppel G, Schildhaus HU, Siveke JT. MCL1 as putative target in pancreatoblastoma. *Virchows Arch*. 2022 Aug;481(2):265-272. (IF 4.54)
116. **Revia S, Seretny A, Wendler L, Banito A, Eckert C, Breuer K, Mayakonda A, Lutsik P, Evert M, Ribback S, Gallage S, Chikh Bakri I, Breuhahn K, Schirmacher P, Heinrich S, Gaida MM, Heikenwälder M, Calvisi DF, Plass C, Lowe SW, Tschaharganeh DF**. **Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer. *Gut*. 2022 Aug;71(8):1613-1628. (IF 31.79)**
117. Rieke DT*, de Bortoli T*, Horak P*, Lamping M, Benary M, Jelas I, Rüter G, Berger J, Zettwitz M, Kagelmann N, Kind A, Fabian F, Beule D, Glimm H, Brors B, **Stenzinger A**, Fröhling S*, Keilholz U*.

- Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards. *BMC Med.* 2022 Oct 24;20(1):367. (IF 11.80)
118. Rios Garcia M, Meissburger B, Chan J, de Guia RM, Mattijssen F, **Roessler S**, Birkenfeld AL, Raschzok N, Riols F, Tokarz J, Giroud M, Gil Lozano M, Hartleben G, Nawroth P, Haid M, López M, Herzig S, Berriel Diaz M. Trip13 Depletion in Liver Cancer Induces a Lipogenic Response Contributing to Plin2-Dependent Mitotic Cell Death. *Adv Sci (Weinh).* 2022 Oct;9(29): e2104291. (IF 17.52)
119. Roeb E*, Canbay A*, Bantel H, Bojunga J, de Laffolie J, Demir M, Denzer UW, Geier A, Hofmann WP, Hudert C, Karlas T, Krawczyk M, **Longerich T**, Luedde T, Roden M, Schattenberg J, Sterneck M, Tannapfel A, Lorenz P, Tacke F*; Collaborators: . Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025. *Z Gastroenterol.* 2022 Sep;60(9):1346-1421. German. (IF 1.76)
120. Roeper J, Christopoulos P, Falk M, Heukamp LC, Tiemann M, **Stenzinger A**, Thomas M, Griesinger F. *TP53* co-mutations as an independent prognostic factor in 2nd and further line therapy-*EGFR* mutated non-small cell lung cancer IV patients treated with osimertinib. *Transl Lung Cancer Res.* 2022 Jan;11(1):4-13. (IF 4.72)
121. Rong C, Grünow J, Thierauf J, **Lucena-Porcel C**, Major G, Holzinger D, Dyckhoff G, Kern J, Lammert A, Scherl C, Rotter N, Plinkert PK, Affolter A. Conjoint analysis of OPRPN and SMR3A protein expression as potential predictive biomarkers for head and neck squamous cell carcinoma after radiotherapy. *Oncol Rep.* 2022 Sep;48(3):159. (IF 4.13)
122. Rossi M*, Altea-Manzano P*, Demicco M, Doglioni G, Bornes L, Fukano M, Vandekerke A, Cuadros AM, Fernández-García J, Riera-Domingo C, Jauset C, Planque M, Alkan HF, Nittner D, Zuo D, Broadfield LA, Parik S, Pane AA, Rizzollo F, Rinaldi G, Zhang T, Teoh ST, Aurora AB, Karras P, Vermeire I, Broekaert D, Elsen JV, Knott MML, Orth MF, Demeyer S, Eelen G, Dobrolecki LE, Bassez A, Brussel TV, Sotlar K, Lewis MT, Bartsch H, Wuhrer M, Veelen PV, Carmeliet P, Cools J, Morrison SJ, Marine JC, Lambrechts D, Mazzone M, Hannon GJ, Lunt SY, **Grünewald TGP**, Park M, Rheenen JV, Fendt SM. PHGDH heterogeneity potentiates cancer cell dissemination and metastasis. *Nature.* 2022 May;605(7911):747-753. **Erratum in:** *Nature.* 2022 Sep;609(7927): E8. (IF 69.50)
123. **Schapiro D***, Sokolov A*, Yapp C*, Chen YA, Muhlich JL, Hess J, Creason AL, Nirmal AJ, Baker GJ, Nariya MK, Lin JR, Maliga Z, Jacobson CA, Hodgman MW, Ruokonen J, Farhi SL, Abbondanza D, McKinley ET, Persson D, Betts C, Sivagnanam S, Regev A, Goecks J, Coffey RJ, Coussens LM, Santagata S, Sorger PK. MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging. *Nat Methods.* 2022 Mar;19(3):311-315. (IF 47.99)
124. **Schapiro D***, Yapp C*, Sokolov A*, Reynolds SM, Chen YA, Sudar D, Xie Y, Muhlich J, Arias-Camison R, Arena S, Taylor AJ, Nikolov M, Tyler M, Lin JR, Burlingame EA; Human Tumor Atlas Network; Chang YH, Farhi SL, Thorsson V, Venkatamohan N, Drewes JL, Pe'er D, Gutman DA, Herrmann MD, Gehlenborg N, Bankhead P, Roland JT, Herndon JM, Snyder MP, Angelo M, Nolan G, Swedlow JR, Schultz N, Merrick DT, Mazzilli SA, Cerami E, Rodig SJ, Santagata S, Sorger PK. MITI minimum information guidelines for highly multiplexed tissue images. *Nat Methods.* 2022 Mar;19(3):262-267. (IF 47.99)
125. Schelbert S, Schindeldecker M, Drebber U, Witzel HR, Weinmann A, Dries V, **Schirmacher P**, Roth W, Straub BK. Lipid Droplet-Associated Proteins Perilipin 1 and 2: Molecular Markers of Steatosis and Microvesicular Steatotic Foci in Chronic Hepatitis C. *Int J Mol Sci.* 2022 Dec 7;23(24):15456. (IF 6.20)
126. Schindler H, Lusky F, Daniello L, Elshiaty M, Gaissmaier L, Benesova K, Souto-Carneiro M, Angeles AK, Janke F, Eichhorn F, **Kazdal D**, Schneider M, Liersch S, Klemm S, Schnitzler P, **Stenzinger A**,

- Sültmann H, Thomas M, Christopoulos P. Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors. *Front Oncol.* 2022 Oct 31;12:1010660. (IF 5.73)
127. Schneider MA, Richtmann S, Gründing AR, Wrenger S, Welte T, Meister M, **Kriegsmann M**, Winter H, Muley T, Janciauskiene S. Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinoma. *Int J Oncol.* 2022 Apr;60(4):39. (IF 5.88)
128. Schrammen PL, Ghaffari Laleh N, Echle A, Truhn D, Schulz V, Brinker TJ, Brenner H, Chang-Claude J, Alwers E, **Brobeil A, Kloor M**, Heij LR, Jäger D, Trautwein C, Grabsch HI, Quirke P, West NP, Hoffmeister M, Kather JN. Weakly supervised annotation-free cancer detection and prediction of genotype in routine histopathology. *J Pathol.* 2022 Jan;256(1):50-60. (IF 9.88)
129. Schuh F, Fink MA, Feisst M, **Eckert C**, Dörr-Harim C, Knebel P, Diener MK, Büchler MW, Mihaljevic AL, Probst P. Protocol of a prospective study investigating the association of PANcreatic parenchymal RISk factors with postoperative pancreatic fistula after partial pancreaticoduodenectomy (PARIS trial). *BMJ Open.* 2022 Apr 13;12(4):e054138. (IF 3.00)
130. Schuller S, Sieker J, Riemenschneider P, Köhler B, Drucker E, **Weiler SME**, Dauch D, Sticht C, **Goepfert B, Roessler S**, Ribback S, **Breuhahn K**, Fend F, Dombrowski F, Singer K, Singer S. HELLS Is Negatively Regulated by Wild-Type P53 in Liver Cancer by a Mechanism Involving P21 and FOXM1. *Cancers (Basel).* 2022 Jan 17;14(2):459. (IF 6.57)
131. **Schwab C, Domke LM, Rose F, Hausser I, Schirmacher P, Longerich T. Cell tropism and viral clearance during SARS-CoV-2 lung infection. *Pathol Res Pract.* 2022 Aug; 236:154000. (IF 3.66)**
132. Seidel C, Hentrich M, Zschäbitz S, Paffenholz P, Heidenreich A, Nestler T, Tran B, Fischer S, Daugaard G, Ochsenreither S, Brito M, Zengerling F, **Schwab C**, Bokemeyer C*, Oing C*. Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG). *World J Urol.* 2022 Feb;40(2):355-361. (IF 3.66)
133. Shavlokhova V, **Flechtenmacher C**, Sandhu S, Vollmer M, Vollmer A, Saravi B, Engel M, Ristow O, Hoffmann J, Freudlsperger C. Ex vivo fluorescent confocal microscopy images of oral mucosa: Tissue atlas and evaluation of the learning curve. *J Biophotonics.* 2022 Feb;15(2):e202100225. (IF 3.39)
134. Sirinian C*, Papanastasiou AD*, Karayel O, Degn SE, Peroukidis S, Chaniotis D, Nonni A, Repanti M, **Kriegsmann M**, Makatsoris T, Koutras A, Mann M, Kalofonos HP. Analysis of RANK-c interaction partners identifies TRAF3 as a critical regulator of breast cancer aggressiveness. *Neoplasia.* 2022 Nov; 33:100836. (IF 6.21)
135. Sloan EA, Gupta R, **Koelsche C**, Chiang J, Villanueva-Meyer JE, Alexandrescu S, Eschbacher JM, Wang W, Mafra M, Ud Din N, Carr-Boyd E, Watson M, Punsoni M, Oviedo A, Gilani A, Kleinschmidt-DeMasters BK, Coss DJ, Lopes MB, Reddy A, Mueller S, Cho SJ, Horvai AE, Lee JC, Pekmezci M, Tihan T, Bollen AW, Rodriguez FJ, Ellison DW, Perry A, von Deimling A, Chang SM, Berger MS, Solomon DA. Intracranial mesenchymal tumors with FET-CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas. *Brain Pathol.* 2022 Jul;32(4): e13037. (IF 7.61)
136. Sobol B*, Azzam Nieto O*, Eberlein EL, Scherr AL, Ismail L, Kessler A, Nader L, Schwab M, Hoffmeister P, Schmitt N, Jäger D, Welte S, Seidensaal K, Christopoulos P, Heilig C, Kriegsmann K, Fröhling S, **Kriegsmann M**, Hess J, Köhler BC. Specific Targeting of Antiapoptotic Bcl-2 Proteins as a Radiosensitizing Approach in Solid Tumors. *Int J Mol Sci.* 2022 Jul 16;23(14):7850. (IF 6.20)
137. Solé-Boldo L, Raddatz G, Gutekunst J, Gilliam O, Bormann F, Liberio MS, Hasche D, **Antonopoulos W**, Mallm JP, Lonsdorf AS, Rodríguez-Paredes M, Lyko F. Differentiation-related epigenomic changes define clinically distinct keratinocyte cancer subclasses. *Mol Syst Biol.* 2022 Sep;18(9): e11073. (IF 12.74)

138. Sorrentino A, Menevse AN, Michels T, Volpin V, Durst FC, Sax J, Xydia M, Hussein A, Stamova S, Spoerl S, Heuschneider N, Muehlbauer J, Jeltsch KM, Rathinasamy A, Werner-Klein M, **Breinig M**, Mikiety D, Kohler C, Poschke I, Purr S, Reidell O, Martins Freire C, Offringa R, Gebhard C, Spang R, Rehli M, Boutros M, Schmidl C, Khandelwal N, Beckhove P. Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activation. *J Immunother Cancer*. 2022 May;10(5):e004258. (IF 12.48)
139. Staemmler H*, Sauer S*, Kreutzer EP, Brandt J, Jordan K, Kreuter M, **Kriegsmann M**, Goldschmidt H, Müller-Tidow C, Egerer G, Kriegsmann K. Quality of Online Information on Multiple Myeloma Available for Laypersons. *Curr Oncol*. 2022 Jun 27;29(7):4522-4540. (IF 3.10)
140. Stögbauer F, Lautizi M, **Kriegsmann M**, Winter H, Muley T, Kriegsmann K, Jesinghaus M, Baumbach J, Schüffler P, Weichert W, Kacprowski T*, Boxberg M*. Tumour cell budding and spread through air spaces in squamous cell carcinoma of the lung - Determination and validation of optimal prognostic cut-offs. *Lung Cancer*. 2022 Jul;169:1-12. (IF 6.08)
141. Strobel O, Lorenz P, Hinz U, Gaida M, König AK, Hank T, Niesen W, Kaiser JÖR, Al-Saeedi M, **Bergmann F**, Springfield C, Berchtold C, Diener MK, Schneider M, Mehrabi A, Müller-Stich BP, Hackert T, Jager D, Büchler MW. Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds? *Ann Surg*. 2022 May 1;275(5):962-971. (IF 13.78)
142. Suwala AK, Felix M, Friedel D, Stichel D, Schrimpf D, Hinz F, Hewer E, Schweizer L, Dohmen H, Pohl U, Staszewski O, Korshunov A, Stein M, Wongsurawat T, Cheunsuacchon P, Sathornsumtee S, **Koelsche C**, Turner C, Le Rhun E, Mühlebner A, Schucht P, Özduman K, Ono T, Shimizu H, Prinz M, Acker T, Herold-Mende C, Kessler T, Wick W, Capper D, Wesseling P, Sahm F, von Deimling A, Hartmann C, Reuss DE. Oligosarcomas, IDH-mutant are distinct and aggressive. *Acta Neuropathol*. 2022 Feb;143(2):263-281. (IF 15.88)
143. Tanevski J, Flores ROR, Gabor A, **Schapiro D**, Saez-Rodriguez J. Explainable multiview framework for dissecting spatial relationships from highly multiplexed data. *Genome Biol*. 2022 Apr 14;23(1):97. (IF 18.01)
144. Tawk B, Wirkner U, Schwager C, Rein K, Zaoui K, Federspil PA, Adeberg S, Linge A, Ganswindt U, Hess J, Unger K, Tinhofer I, Budach V, Lohaus F, Krause M, Guberina M, Stuschke M, Balermipas P, Rödel C, Grosu AL, Schäfer H, Zips D, Combs SE, Pigorsch S, Zitzelsberger H, Baumeister P, Kirchner T, Bewerunge-Hudler M, Weichert W, Hess J, **Herpel E**, Belka C, Baumann M, Debus J, Abdollahi A; DTK-ROG. Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy. *Int J Cancer*. 2022 Feb 15;150(4):603-616. (IF 7.31)
145. **Thomann S, Tóth M, Sprengel SD, Liermann J, Schirmacher P**. Digital Staging of Hepatic Hemangiomas Reveals Spatial Heterogeneity in Endothelial Cell Composition and Vascular Senescence. *J Histochem Cytochem*. 2022 Jul;70(7):531-541. (IF 4.13)
146. Thomas B, Bigdeli AK, Nolte S, Gazyakan E, Harhaus L, Bischel O, Lehner B, Egerer G, **Mechtersheimer G**, Hohenberger P, Horch RE, Andreou D, Schmitt J, Schuler MK, Eichler M, Kneser U. The Therapeutic Role of Plastic and Reconstructive Surgery in the Interdisciplinary Treatment of Soft-Tissue Sarcomas in Germany-Cross-Sectional Results of a Prospective Nationwide Observational Study (PROSa). *Cancers (Basel)*. 2022 Sep 2;14(17):4312. (IF 6.57)
147. **Tomczak A, Springfield C, Dill MT, Chang DH, Kazdal D, Wagner U, Mehrabi A, Brockschmidt A, Luedde T, Naumann P, Stenzinger A, Schirmacher P, Longerich T**. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice. *Br J Cancer*. 2022 Nov;127(9):1701-1708. (IF 9.08)

148. Trefzer TB, Schneider MA, Jechow K, Chua RL, Muley T, Winter H, **Kriegsmann M**, Meister M, Eils R, Conrad C. Intratumoral Heterogeneity and Immune Modulation in Lung Adenocarcinoma in Female Smokers and Never Smokers. *Cancer Res.* 2022 Sep 2;82(17):3116-3129. (IF 13.31)
149. Ventura-Cots M, Argemi J, Jones PD, Lackner C, El Hag M, Abraldes JG, Alvarado E, Clemente A, Ravi S, Alves A, Alborai M, Altamirano J, Barace S, Bosques F, Brown R, Caballeria J, Cabezas J, Carvalhana S, Cortez-Pinto H, Costa A, Degré D, Fernandez-Carrillo C, Ganne-Carrie N, Garcia-Tsao G, Genesca J, Koskinas J, Lanthier N, Louvet A, Lozano JJ, Lucey MR, Masson S, Mathurin P, Mendez-Sanchez N, Miquel R, Moreno C, Mounajjed T, Odena G, Kim W, Sancho-Bru P, Warren Sands R, Szafranska J, Verset L, Schnabl B, Sempoux C, Shah V, Shawcross DL, Stauber RE, **Straub BK**, Verna E, Tiniakos D, Trépo E, Vargas V, Villanueva C, Woosley JT, Ziol M, Mueller S, Stärkel P, Bataller R. Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. *Gut.* 2022 Sep;71(9):1856-1866. (IF 31.79)
150. Vibert J, Saulnier O, Collin C, Petit F, Borgman KJE, Vigneau J, Gautier M, Zaidi S, Pierron G, Watson S, Gruel N, Hénon C, Postel-Vinay S, Deloger M, Raynal V, Baulande S, Laud-Duval K, Hill V, Grossetête S, Dingli F, Loew D, Torrejon J, Ayrault O, Orth MF, **Grünewald TGP**, Surdez D, Coulon A, Waterfall JJ, Delattre O. Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions. *Mol Cell.* 2022 Jul 7;82(13):2458-2471.e9. (IF 19.32)
151. Vickovic S, **Schapiro D***, Carlberg K*, Lötstedt B*, Larsson L*, Hildebrandt F, Korotkova M, Hensvold AH, Catrina AI, Sorger PK, Malmström V, Regev A, Ståhl PL. Three-dimensional spatial transcriptomics uncovers cell type localizations in the human rheumatoid arthritis synovium. *Commun Biol.* 2022 Feb 11;5(1):129. (IF 6.54)
152. Voeltzke K, Scharov K, Funk CM, Kahler A, Picard D, Hauffe L, Orth MF, Remke M, Esposito I, Kirchner T, Schramm A, Rotblat B, **Grünewald TGP**, Reifenberger G, Leprivier G. EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastoma. *Cell Death Discov.* 2022 Apr 4;8(1):157. (IF 7.11)
153. Voesch S, Bitzer M, Albert J, Bartenstein P, Bechstein W, Blödt S, Brunner T, Dombrowski F, Evert M, Follmann M, La Fougère C, Freudenberger P, Geier A, Gkika E, Martin G, Hammes E, Helmberger T, Hoffmann RT, Hofmann, WP, Huppert P, Kautz A, Knötgen G, Körber J, Krug D, Lammert F, Lang H, Langer T, Lenz P, Mahnken A, Meining A, Micke O, Nadalin S, Nguyen HP, Ockenga J, Oldhafer KJ, Paprottka P, Paradies K, Pereira P, Persigehl T, Plauth M, Plentz R, Pohl J, Riemer J, Reimer P, Ringwald J, Ritterbusch U, Roeb E, Schellhaas B, **Schirmacher P**, Schmid I, Schuler A, von Schweinitz D, Seehofer D, Sinn M, Stein A, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Trojan J, van Thiel I, Tholen R, Vogel A, Vogl T, Vorwerk H, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wittekind C, Wörns MA, Galle P, Malek N. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms – Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL. *Z Gastroenterol.* 2022 Jan;60(1):81-107. German. (IF 1.76)
154. Voesch S, Bitzer M, Albert J, Bartenstein P, Bechstein W, Blödt S, Brunner T, Dombrowski F, Evert M, Follmann M, La Fougère C, Freudenberger P, Geier A, Gkika E, Martin G, Hammes E, Helmberger T, Hoffmann RT, Hofmann, WP, Huppert P, Kautz A, Knötgen G, Körber J, Krug D, Lammert F, Lang H, Langer T, Lenz P, Mahnken A, Meining A, Micke O, Nadalin S, Nguyen HP, Ockenga J, Oldhafer KJ, Paprottka P, Paradies K, Pereira P, Persigehl T, Plauth M, Plentz R, Pohl J, Riemer J, Reimer P, Ringwald J, Ritterbusch U, Roeb E, Schellhaas B, **Schirmacher P**, Schmid I, Schuler A, von Schweinitz D, Seehofer D, Sinn M, Stein A, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Trojan J, van Thiel I, Tholen R, Vogel A, Vogl T, Vorwerk H, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wittekind C, Wörns MA, Galle P, Malek N. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms-Langversion 2.0-Juni 2021,

- AWMF-Registernummer : 021-053OL. Z Gastroenterol. 2022 Jan;60(1):e56-e130. German. (IF 1.76)
155. Vogeser M, Brüggemann M, Lennerz J, **Stenzinger A**, Gassner UM. Partial Postponement of the Application of the In Vitro Diagnostic Medical Devices Regulation in the European Union. Clin Chem. 2022 Jun 1;68(6):856-857. (IF 12.11)
 156. Vogt PH, Besikoglu B, Bettendorf M, Frank-Herrmann P, Zimmer J, Bender U, Knauer-Fischer S, Choukair D, **Sinn P**, Doerr HG, Woelfle J, Heidemann PH, Lau YC, Strowitzki T. Sex chromosome DSD individuals with mosaic 45,X0 and aberrant Y chromosomes in 46,XY cells: distinct gender phenotypes and germ cell tumour risks⁵. Syst Biol Reprod Med. 2022 Aug;68(4):247-257. (IF 2.95)
 157. Walle T, Kraske JA, Liao B, Lenoir B, Timke C, von Bohlen Und Halbach E, Tran F, Griebel P, Albrecht D, Ahmed A, Suarez-Carmona M, Jiménez-Sánchez A, Beikert T, Tietz-Dahlfuß A, Menevse AN, Schmidt G, Brom M, Pahl JHW, **Antonopoulos W**, Miller M, Perez RL, Bestvater F, Giese NA, Beckhove P, Rosenstiel P, Jäger D, Strobel O, Pe'er D, Halama N, Debus J, Cerwenka A, Huber PE. Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8. Sci Adv. 2022 Mar 25;8(12): eabh4050. (IF 14.98)
 158. Wang H, Zhou Y, Xu H, Wang X, Zhang Y, Shang R, O'Farrell M, **Roessler S**, Sticht C, Stahl A, Evert M, Calvisi DF, Zeng Y, Chen X. Therapeutic efficacy of FASN inhibition in preclinical models of HCC. Hepatology. 2022 Oct;76(4):951-966. (IF 17.29)
 159. **Wehling L**, Keegan L, **Fernández-Palanca P**, Hassan R, Ghallab A, **Schmitt J**, **Tang Y**, **Le Marois M**, **Roessler S**, **Schirmacher P**, Kummer U, Hengstler JG, Sahle S*, **Breuhahn K***. Spatial modeling reveals nuclear phosphorylation and subcellular shuttling of YAP upon drug-induced liver injury. *Elife*. 2022 Oct 18;11:e78540. (IF 8.71)
 160. Wierz M, Sauerbrei B, Wandernoth P, **Kriegsmann M**, Casadonte R, Kriegsmann K, Kriegsmann J. Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) including Variant Analysis by Mass Spectrometry in Placental Tissue. Viruses. 2022 Mar 14;14(3):604. (IF 5.81)
 161. Wiggenhauser LM, Metzger L, Bennewitz K, Soleymani S, Boger M, Tabler CT, **Hausser I**, Sticht C, Wohlfart P, Volk N, Heidenreich E, Buettner M, Hammes HP, Kroll J. pdx1 Knockout Leads to a Diabetic Nephropathy- Like Phenotype in Zebrafish and Identifies Phosphatidylethanolamine as Metabolite Promoting Early Diabetic Kidney Damage. Diabetes. 2022 May 1;71(5):1073-1080. (IF 9.30)
 162. Wohlfart DP, Lou B, Middel CS, Morgenstern J, Fleming T, Sticht C, **Hausser I**, Hell R, Hammes HP, Szendrödi J, Nawroth PP, Kroll J. Accumulation of acetaldehyde in ald2.1^{-/-} zebrafish causes increased retinal angiogenesis and impaired glucose metabolism. Redox Biol. 2022 Apr; 50:102249. (IF 10.78)
 163. Wolff G, Sakurai M, Mhamane A, Troullinaki M, Maida A, Deligiannis IK, Yin K, Weber P, Morgenstern J, Wieder A, Kwon Y, Sekar R, Zeigerer A, Roden M, Blüher M, **Volk N**, **Poth T**, Hackert T, Wiedmann L, De Angelis Rigotti F, Rodriguez-Vita J, Fischer A, Mukthavaram R, Limphong P, Tachikawa K, Karmali P, Payne J, Chivukula P, Ekim-Üstünel B, Martinez-Jimenez CP, Szendrödi J, Nawroth P, Herzig S. Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function. Mol Metab. 2022 Jun; 60:101487. (IF 8.56)
 164. Yamada Y, Belharazem-Vitacolonna D, Bohnenberger H, Weiß C, Matsui N, **Kriegsmann M**, Kriegsmann K, **Sinn P**, Simon-Keller K, Hamilton G, Graeter T, Preissler G, Ott G, Schölch S, Nakajima N, Yoshizawa A, Haga H, Date H, Thomas RK, Petrini I, Giaccone G, Ströbel P, Marx A. Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities. Cell Death Dis. 2022 Nov 19;13(11):979. (IF 7.11)

165. Yamada Y, Bohnenberger H, **Kriegsmann M**, Kriegsmann K, **Sinn P**, Goto N, Nakanishi Y, Seno H, Chigusa Y, Fujimoto M, Minamiguchi S, Haga H, Simon R, Sauter G, Ströbel P, Marx A. Tuft cell-like carcinomas: novel cancer subsets present in multiple organs sharing a unique gene expression signature. *Br J Cancer*. 2022 Nov;127(10):1876-1885. (IF 9.08)
166. Yaung SJ, Woestmann C, Ju C, Ma XM, Gattam S, Zhou Y, Xi L, Pal S, Balasubramanyam A, Tikoo N, Heussel CP, Thomas M, **Kriegsmann M**, Meister M, Schneider MA, Herth FJ, Wehnl B, Diehn M, Alizadeh AA, Palma JF, Muley T. Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. *Cancers (Basel)*. 2022 May 18;14(10):2479. (IF 6.57)
167. Zhang KS, Schelb P, Netzer N, Tavakoli AA, Keymling M, Wehrse E, Hog R, Rotkopf LT, Wennmann M, Glemser PA, Thierjung H, von Knebel Doeberitz N, Kleesiek J, Görtz M, Schütz V, Hielscher T, **Stenzinger A**, Hohenfellner M, Schlemmer HP, Maier-Hein K, Bonekamp D. Pseudoprospective Paraclinical Interaction of Radiology Residents with a Deep Learning System for Prostate Cancer Detection: Experience, Performance, and Identification of the Need for Intermittent Recalibration. *Invest Radiol*. 2022 Sep 1;57(9):601-612. (IF 10.06)
168. Zhang X, Schalke B, Kvell K, Kriegsmann K, **Kriegsmann M**, Graeter T, Preissler G, Ott G, Kurz K, Bulut E, Ströbel P, Marx A, Belharazem D. WNT4 overexpression and secretion in thymic epithelial tumors drive an autocrine loop in tumor cells *in vitro*. *Front Oncol*. 2022 Jul 29;12:920871. (IF 5.73)

REVIEWS AND OTHER PUBLICATIONS

1. Ahmed A, Ata F, Gaber M, Petkar M, Mahfouz A, **Schirmacher P**, Musa S, Hashim A. Refractory Hyperammonemic encephalopathy in Fibrolamellar hepatocellular carcinoma, a case report and literature review. *Curr Probl Cancer*. 2022 Jun;46(3):100847. (IF 2.36)
2. **Albrecht T**, Bauer-Auch C, Winzler C, Surovtsova I, **Rossberg A**, **Schirmacher P**, Morakis P. Wissenschaftliche Nutzung von Krebsregisterdaten bei seltenen Tumorerkrankungen am Beispiel des hepatischen Angiosarkoms. *Forum*. 2022 37:318-320. (no IF)
3. **Albrecht T**, **Schirmacher P**. Das hepatitische Angiosarkom: eine rare Entität mit gewandelter Risikokonstellation. *Landesqualitätsbericht Onkologie Baden-Württemberg 2022, Gastbeitrag Pathologie*, 113-114. (no IF)
4. **Ball M**, Christopoulos P, **Kirchner M**, **Allgäuer M**, **Brandt R**, Winter H, Heußel CP, Herth F, Fröhling S, Savai R, **Kriegsmann M**, **Schirmacher P**, Peters S, Thomas M, **Stenzinger A**, **Kazdal D**. Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report. *Cold Spring Harb Mol Case Stud*. 2022 Apr 28;8(3): a006156. (IF 2.32)
5. Cidre-Aranaz F, Watson S, Amatruda JF, Nakamura T, Delattre O, de Alava E, Dirksen U, **Grünewald TGP**. Small round cell sarcomas. *Nat Rev Dis Primers*. 2022 Oct 6;8(1):66 (IF 65.03)
6. Ditsch N, Wöcke A, Untch M, Jackisch C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Fallenberg EM, Fasching PA, Fehm TN, Friedrich M, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Kreipe HH, Krug D, Kühn T, Kümmel S, Kolberg-Liedtke C, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, **Sinn HP**, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Witzel I, Müller V, Janni W, Thill M. AGO Recommendations for the Diagnosis and Treatment of

- Patients with Early Breast Cancer: Update 2022. *Breast Care (Basel)*. 2022 Aug;17(4):403-420. (IF 2.26)
7. Feurstein S, Zoller J, **Schwab C**, Schreiner S, Mundt H, Breitzkreutz I, Schneider B, Beimler J, Zeier M, **Waldherr R**, Gröschel S, Müller-Tidow C, Schönland SO, Hegenbart U. Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior-A case report. *EJHaem*. 2022 Sep 8;3(4):1377-1380. (IF 3.67)
 8. **Goepfert B, Roessler S**. New kid on the block: Netrin-1 as a novel player in the delicate molecular network of hepatic inflammation. *Hepatology*. 2022 Nov;76(5):1237-1239. (IF 17.29)
 9. Horak P, **Leichsenring J, Goldschmid H**, Kreutzfeldt S, **Kazdal D**, Teleanu V, **Endris V**, Geldon L, **Allgäuer M, Volckmar AL**, Dikow N, Renner M, **Kirchner M, Penzel R, Ploeger C, Brandt R, Seker-Cin H, Budczies J**, Heilig CE, **Neumann O**, Schaaf CP, **Schirmacher P**, Fröhling S, **Stenzinger A**. Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. *Genes Chromosomes Cancer*. 2022 Jun;61(6):303-313. (IF 4.26)
 10. Jonigk D*, Werlein C*, Acker T, Aepfelbacher M, Amann KU, Baretton G, Barth P, Bohle RM, Büttner A, Büttner R, Dettmeyer R, Eichhorn P, Elez Kurtaj S, Esposito I, Evert K, Evert M, Fend F, Gaßler N, Gattenlöhner S, Glatzel M, Göbel H, Gradhand E, Hansen T, Hartmann A, Heinemann A, Heppner FL, Hilsenbeck J, Horst D, Kamp JC, Mall G, Märkl B, Ondruschka B, Pablik J, Pfefferle S, Quaas A, Radbruch H, Röcken C, Rosenwald A, Roth W, Rudelius M, **Schirmacher P**, Slotta-Huspenina J, Smith K, Sommer L, Stock K, Ströbel P, Strobl S, Titze U, Weirich G, Weis J, Werner M, Wickenhauser C, Wiech T, Wild P, Welte T, von Stillfried S*, Boor P*. Organ manifestations of COVID-19: what have we learned so far (not only) from autopsies? *Virchows Arch*. 2022 Aug;481(2):139-159. (IF 4.54)
 11. **Kahles A, Goldschmid H, Volckmar AL, Plöger C, Kazdal D, Penzel R, Budczies J, Kempny G, Kazmierczak M, Flechtenmacher C**, Baretton G, Weichert W, Horst D, Klauschen F, Gassner UM, Brüggemann M, Vogeser M, **Schirmacher P, Stenzinger A**. Struktur und Inhalt der EU-IVDR : Bestandsaufnahme und Implikationen für die Pathologie [Structure and content of the EU-IVDR : Current status and implications for pathology]. *Pathologie (Heidelb)*. 2022 Sep;43(5):351-364. German. (IF 0.97)
 12. **Kaufhold-Wedel C, Hummel M, Brobeil A, Schirmacher P, Schmitt S**. Qualitätssicherung im Gewebebiobanking – Ein Überblick [Quality assurance in tissue biobanking-an overview]. *Pathologie (Heidelb)*. 2022 Sep;43(5):365-371. German. (IF 0.97)
 13. **Kazdal D**, Hofman V, Christopoulos P, Ilié M, **Stenzinger A**, Hofman P. Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications. *Genes Chromosomes Cancer*. 2022 May;61(5):244-260. (IF 4.26)
 14. **Koelsche C**, von Deimling A. Methylation classifiers: Brain tumors, sarcomas, and what's next. *Genes Chromosomes Cancer*. 2022 Jun;61(6):346-355. (IF 4.26)
 15. **Kommos FKF, Kölsche C**, Mentzel T, Schmidt D, von Deimling A, McCluggage WG, Kommos F. Spindle Cell Sarcoma of the Uterine Corpus with Adipose Metaplasia: Expanding the Morphologic Spectrum of Neoplasms With MEIS1-NCOA2 Gene Fusion. *Int J Gynecol Pathol*. 2022 Jul 1;41(4):417-422. (IF 3.32)
 16. Lehmann U, **Stenzinger A**. Das molekularpathologische Brevier: Allelfrequenzen in der NGS-Analytik [The molecular pathological breviary: allele frequencies in NGS analysis]. *Pathologie*. 2022 Mar;43(2):154-156. German. (IF 0.97)
 17. Lehmann U, **Stenzinger A**. Das molekularpathologische Brevier: Lesetiefe und Coverage in der NGS-Analytik [The molecular pathology breviary: read depth and coverage in NGS analysis]. *Pathologie*. 2022 Feb;43(1):65-66. German. (IF 0.97)
 18. Lehmann U, **Stenzinger A**. Das molekularpathologische Brevier: Was heißt: „WGS, WES, Transkriptom, RNAseq“? [The molecular pathology breviary: What do "WGS, WES,

- transcriptome, RNAseq" mean?]. *Pathologie (Heidelb)*. 2022 Jul;43(4):317-318. German. (IF 0.97)
19. Lehmann U, **Stenzinger A**. Das molekularpathologische Brevier: was heißt: „hybrid capture“, „anchored multiplex PCR“ und ampliconbasiert? [The molecular pathology breviary: what do hybrid capture, anchored multiplex PCR and amplicon-based mean?]. *Pathologie*. 2022 May;43(3):229-230. German. (IF 0.97)
 20. **Longerich T, Schirmacher P**. Pathologie des Hepatozellulären Karzinoms [Pathology of hepatocellular carcinoma]. *Pathologie*. 2022 Feb;43(1):67-78. German. (IF 0.97)
 21. Shah R, Klotz LV, **Glade J**. Current Management and Future Perspective in Pleural Mesothelioma. *Cancers (Basel)*. 2022 Feb 18;14(4):1044. (IF 6.57)
 22. Shulman DS, Whittle SB, Surdez D, Bailey KM, de Álava E, Yustein JT, Shlien A, Hayashi M, Bishop AJR, Crompton BD, DuBois SG, Shukla N, Leavey PJ, Lessnick SL, Kovar H, Delattre O, **Grünewald TGP**, Antonescu CR, Roberts RD, Toretsky JA, Tirode F, Gorlick R, Janeway KA, Reed D, Lawlor ER, Grohar PJ. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. *NPJ Precis Oncol*. 2022 Sep 17;6(1):65. (IF 10.12)
 23. Sirinian C, Peroukidis S, Kriegsmann K, Chaniotis D, Koutras A, **Kriegsmann M**, Papanastasiou AD. Cellular Senescence in Normal Mammary Gland and Breast Cancer. Implications for Cancer Therapy. *Genes (Basel)*. 2022 Jun 1;13(6):994. (IF 4.14)
 24. **Stenzinger A***, Edsjö A*, **Ploeger C**, Friedman M, Fröhling S, Wirta V, Seufferlein T, Botling J, Duyster J, Akhras M, Thimme R, Fioretos T, Bitzer M, Cavellier L*, **Schirmacher P***, Malek N*, Rosenquist R*; GMS working group and ZPM working group. Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. *Semin Cancer Biol*. 2022 Sep; 84:242-254. (IF 17.01)
 25. **Stenzinger A**, Alber M, **Allgäuer M**, Jurmeister P, Bockmayr M, **Budczies J**, Lennerz J, Eschrich J, **Kazdal D**, **Schirmacher P**, Wagner AH, Tacke F, Capper D, Müller KR, Klauschen F. Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling. *Semin Cancer Biol*. 2022 Sep; 84:129-143. (IF 17.01)
 26. Stewart MD, Merino Vega D, Arend RC, Baden JF, Barbash O, Beaubier N, Collins G, French T, Ghahramani N, Hinson P, Jelinic P, Marton MJ, McGregor K, Parsons J, Ramamurthy L, Sausen M, Sokol ES, **Stenzinger A**, Stires H, Timms KM, Turco D, Wang I, Williams JA, Wong-Ho E, Allen J. Homologous Recombination Deficiency: Concepts, Definitions, and Assays. *Oncologist*. 2022 Mar 11;27(3):167-174. (IF 5.83)
 27. Thill M, Lüftner D, Kolberg-Liedtke C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Fallenberg EM, Fasching PA, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Jackisch C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, **Sinn HP**, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Janni W, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. *Breast Care (Basel)*. 2022 Aug;17(4):421-429. (IF 2.26)
 28. **Vogel A, Schirmacher P**. Drug Report Pemigatinib. 2022 Sept; 1-12 (no IF)
 29. Wiedemann C*, **Kazdal D***, Cvetkovic J, Kunz J, Fisch D, **Kirchner M**, **Kriegsmann M**, Sültmann H, Heussel CP, Bischoff H, Thomas M, **Stenzinger A**, Christopoulos P. Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report. *Cold Spring Harb Mol Case Stud*. 2022 Oct 28;8(6): a006234. (no IF)

Book chapters

1. Wandernoth P, Kriegsmann K, Kriegsmann J, Kriegsmann M. Detection of SARS-CoV-2 by Mass Spectrometry. In: *Methods Mol Biol.* 2022; Vol: 2452: S.183-196, ISBN doi: 10.1007/978-1-0716-2111-0_12. PMID: 35554908.
2. Gessi M, Bastian BC, Kölsche C, Küsters-Vandeveldel H. Circumscribed meningeal melanocytic neoplasms: Melanocytoma and melanoma. In: *WHO Classification of Tumours series, 2022, 5th edition Vol.6*, S.344-349, ISBN 978-92-832-4508-7